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1 Introduction 
Living organisms are made up of one or more cells, can grow, reproduce, process 
information, carry out chemical reactions, and respond to stimuli 1. Information transfer is a 
necessary precedent to responsiveness of cells to stimuli in their environment. The route of 
information transfer in living organisms cannot be a one-way street, though. Coordination in 
multicellular organisms requires feedback mechanisms between cells and to the environment. 
This must allow cells to respond to different challenges swiftly and accurately. 
There is no doubt to the role of nucleic acids and amino acids in coding information in form 
of DNA, RNA and protein. However, it is becoming clearer that the whole story is not told, 
when describing the genome and proteome as the only hardware coding information of living 
organisms. In the concept of the genetic code, a new concept is emerging: the sugar code 2, 3. 
This describes glycans as a third class of bio-informative macromolecules, next to nucleic 
acids and proteins. As a first step, the complexity of all glycans being produced by an 
organism, the glycome, is being identified 4. In the past, the lack of possibilities to analyze 
glycan chains in detail was a main reason why scientists did not pay adequate attention to the 
potential information-encoding system hidden in sugar structures. Today, sophisticated 
analytical procedures are at hand and thus these problems have been elegantly mastered 5, 6, 7. 
Therefore in the next chapter, the view can be focused on saccharides as possible coding 
units. 
1.1 Glycans and Their Still Underappreciated Role 
as a Carrier of Information 
Carbohydrates are well known as carriers of energy, such as starch and glycogen, and as main 
structural elements in plants and insects, such as cellulose and chitin. One noteworthy 
common characteristic of these four examples is, as very different as their form and function 
may be, that all are polysaccharides made up of repeating units of glucose, connected via the 
C1 and C4 carbon atoms. Differences between the anomeric linkage (α-D-glucose in starch 
and glycogen,  or β-D-glucose in cellulose) or N-acetylation of C2 (β-D-N-acetylglucosamine 
in chitin) results in the diversity of the final structures. 
Introduction 
 
2 
Nucleic acids and amino acids encode information by being linked to each other in a specific 
order. Each single element has enough structural diversity from the other elements to be 
distinct. The question as to whether sugars also meet these requirements will now be 
addressed. The here presented reasoning to the importance of sugars follows the guidelines 
provided by Gabius et al. 3. These authors emphasize the meaning and validity of the sugar 
code as an information carrier. The pyranose/furanose ring of monosaccharides presents many 
hydroxyl groups suitable for donor/acceptor bonds or for coordination bonds with cation such 
as Ca2+. The sugar D-galactose has a set of weakly polarized C-H bonds, one side of 
C-H/π-electron and van der Waals interactions. This makes stacking to aromatic ring systems 
possible, e.g. to the indolyl ring of tryptophan. The sugar D-galactose can also be used to 
exemplify the consequences of changes in positioning of a hydroxyl group in epimers. As in 
other monosaccharides, shifting the hydroxyl group to the other side of the ring will affect the 
potential for directional hydrogen bonds. An additional consequence will be a change in the 
areas of hydrophobicity specific for galactose. This shows that the positioning of the hydroxyl 
groups can clearly distinguish two monosaccharides from each other 3, 8, 9, 10. Introducing a 
substituent such as a sulfate group to a free hydroxyl group demonstrates an additional 
possibility to change one element of recognition. The activity of a heparan sulfate 
glucosaminyl 3-O-sulfotransferase is responsible for the generation of antithrombin-III 
binding sites 11. The glycosaminoglycan glycan chain is made up of repetitive units of 
GlcNα1,4GlcAβ1,4. At first sight, this is a monotonous structure, hardly capable of storing 
information or regulating coagulation. But by site specific epimerization and sulfation, 
regulated by enzymatic activity, the necessary complexity is achieved to specifically activate 
antithrombin-III upon binding. Thus, as nucleic acids and amino acids, monosaccharides 
fulfill the requirements to be clearly distinguished from another, comparable to separate 
letters of an alphabet. 
Forming these letters to words, nucleic acids and amino acids are covalently linked to each 
other. The manner of connecting the units follows the same pattern along the chain. Sugars, 
however, can be connected with a larger amount of variation. The glycosidic bond connecting 
the C1 carbon atom can be linked to different hydroxyl groups of the next monosaccharide. 
Moreover, the binding is not sufficiently defined by the number of the two linked carbon 
atoms, but must also include the anomeric positioning of C1. A further deviation between the 
linkage of sugars compared with the linkage of amino acids or nucleic acids is the fact that 
saccharides can form branched chains. Taken together, the total of different combinations 
linking the building blocks together in monosaccharides surpasses the possibilities in amino 
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acids or nucleic acids by many orders of magnitude 12. This comparison clearly proves 
glycans to be potential carriers of information with the ability to form many words with only a 
few letters. 
For information in sugars to be read, these must be spatially accessible. Indeed the glycan 
chains of membrane glycoconjugates reach out to the environment. They are therefore ideally 
located to serve as docking sites for sensors of other cells as well as of bacteria, viruses and 
protozoa. When proteins are glycosylated, glycan branches move away considerably (in the 
range of about 3 nm) from the peptide-sugar linkage point 13. Their conformational behavior 
can often be considered as being essentially independent from the protein surface. Compared 
to phosphorylation as another well known form of post translational modification, 
glycosylation actually surpasses phosphorylation in terms of structural complexity, frequency 
of occurrence, and diversity of bond formation, with a total of at least 41 ways for connecting 
carbohydrates covalently to proteins 14, 15, 16, 17, 18. Reversible protein phosphorylation is a well 
known means of swiftly modulating protein activation and generating docking sites for other 
proteins. These attributes may also be conferred to the protein by glycosylation. An 
implication for the importance of protein glycosylation is given by the fact that many 
enzymes are responsible for glycan assembly and processing. Especially concerning enzymes 
with specificity for sugars that are located at the spatially accessible tips of the glycan chains. 
At least 13 separate enzymes can attach galactose in β1,4- or  β1,3-position to an acceptor 
chain 19, 20, 21. Human sialyltransferases form a functional family of at least 18 different, 
Golgi-membrane-bound enzymes 22. As discussed above, modification of monosaccharides by 
introducing a substituent to a free hydroxyl group is an excellent way to change the properties 
of a sugar into a new distinct unit with different characteristics. In a figurative sense, 
substitution increases the number of letters of the sugar alphabet and changes the meaning of 
the words spelled out. Also implying functionality, at least 23 mammalian sulfotransferases 
are characterized to introduce this group into different acceptors from N- and O-glycans and 
glycosaminoglycans 23, 24, 25, 26.  
The pattern of distribution of glycans in cells and tissues appears to be tightly 
regulated 27, 28, 29, 30, 31, 32, 33. It is unlikely that this occurs without reason. Importantly, this is 
also true for malignant aberrations. Alterations in the glycosylation profile accompany disease 
onset and progression 34, 35, 36, 37, 38, 39. A major route to define the molecular basis of a disease 
is to correlate a lack of function with the syndrome. Impaired function of a distinct protein in 
glycan metabolism has indeed been associated with disease. For instance, leukocyte adhesion 
deficiency syndrome II (LAD II) is characterized by recurrent infections and marked 
Introduction 
 
4 
neutrophilia during infection 40. Severe mental and growth retardation demonstrates 
consequences of the defect beyond the immune system. The molecular cause of the symptoms 
was finally linked to a mutation in the GDP-fucose transporter 41. The ensuing impairment of 
synthesis of sialylated/sulfated Lewis determinants has been a crucial factor to understand the 
role of fucose incorporation as the first step of leukocyte adhesion in vivo, i.e. to establish the 
initial contact between the leukocytes in the bloodstream and the activated endothelium 42, 43. 
An explanation for the development of mental and growth retardation has currently not been 
found. Further investigations are necessary to delineate the role of fucosylation in the 
development of these symptoms in LAD II. An additional example of a glycosylation defect 
being responsible for disease development is given in lysosomal storage disease 
(mucolipodoses) 17, 44. In type II (I-cell disease), type IIIA (pseudo-Hurler polydystrophy) and 
type IIIC (variant pseudo-Hurler polydystrophy) forms, a common mechanism in targeting 
lysosomal enzymes to their destination is affected: the decoration of N-glycans of enzymes 
destined to reach the lysosome with the mannose-6-phosphate signal, i.e. the reaction of the 
UDP-N-acetylglucosamine: lysosomal enzyme N-acetylglucosamine-1-phosphotransferase, 
either by abrogating (type II) or reducing its catalytic capacity (IIIA) or its target recognition 
(IIIC) 44 ,45. Patients with I-cell disease suffer severe psychomotor retardation and skeletal 
deformities. Their lysosomes contain large inclusions of undigested glycosaminoglycans and 
glycolipids. At least eight acid hydrolases required for the degradation of the inclusions are 
missing from the affected lysosomes. In contrast, very high levels of the enzymes are present 
in blood and urine 46. Having thus shown the possibilities and the importance of glycosylation, 
the view will be focused on the next step of information processing. Obviously, the 
information encoded in sugars must be read for it to be of purpose. Taking nucleic acids as 
carriers of information as an example, there is a large array of DNA-binding proteins 
available helping to read the information encoded in the arrangement of nucleic acids. 
Therefore, it is pertinent to ask whether carbohydrate-binding proteins beyond those 
responsible for enzymatic processing exist, which recognize the distinct combinations and 
arrangements of glycans. 
1.2 Translation of the Sugar Code 
Carbohydrate-binding proteins were historically first identified as agglutinins by S. Weir 
Mitchell in venom of the tropical rattlesnake (Crotalus durissus) in 1860 47, 48. Their 
interaction with carbohydrates was first recognized in 1936 by J.B. Sumner and S.F. 
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Howell 49. The property of these proteins to select (Latin, legere) certain carbohydrate 
epitopes in binding helped to define the chemical nature of the ABH-blood group 
epitopes 50, 51, 52, 53. Because of this selecting ability, W.C. Boyd introduced the term lectin (the 
past participle of legere) in the year 1954 to describe these proteins 54. The above mentioned 
happenings and other key events in the history of lectins are shown in table 1.  
Table 1. Brief historical account of lectinology 
1860 Observation of blood ”coagulation” by rattlesnake venom (S. W. Mitchell) 
1888 Detection of erythrocyte agglutination by protein fractions from castor beans 
and other plant seeds (H. Stillmark) 
1891 Toxic plant agglutinins applied as model antigens (P. Ehrlich) 
1898 Introduction of the term ”haemagglutinin” or phytohaemagglutinin for plant 
proteins that agglutinate red blood cells (M. Elfstrand) 
1902 Detection of bacterial agglutinins (R. Kraus) 
1902 Demonstration that blood ”coagulation” by snake venom (later shown to 
depend on a C-type lectin) observed in 1860 was not due to blood clotting 
but to cell agglutination (S. Flexner, H. Noguchi) 
1906 Detection of an agglutinin in bovine serum (later characterized as the C-type 
lectin conglutinin) acting on activated complement-coated erythrocytes 
(J. Bordet, F. P. Gay) 
1907 Detection of non-toxic agglutinins in plants (K. Landsteiner, H. Raubitschek) 
1913 Use of intact cells for the purification of lectins (R. Kobert) 
1919 Crystallization of a lectin, concanavalin A (J. B. Sumner) 
1936 Precipitation of starch, glycogen and mucins by concanavalin A and its 
interaction with stromata of erythrocytes define carbohydrate as ligand (J. B. 
Sumner, S. F. Howell) 
1941 Detection of viral agglutinins (G. K. Hirst) 
1947/48 Detection of lectins specific for human blood groups (W. C. Boyd, K. O. 
Renkonen) 
1952 Carbohydrate nature of blood group determinants proven by lectin-mediated 
agglutination and its sugar-dependent inhibition (W. M. Watkins, W. T. J. 
Morgan) 
1954 Introduction of the term ”lectin” for plant agglutinins, primarily for those 
which are blood group-specific (W. C. Boyd) 
1960 Detection of the mitogenic potency of lectins toward lymphocytes (P. C. 
Nowell) 
1965 Application of affinity chromatography for the isolation of lectins (I. J. 
Goldstein, B. B. L. Agrawal) 
1972 Determination of the amino acid sequence and the three-dimensional 
structure of a lectin, concanavalin A (G. M. Edelman, K. O. Hardman, C. F. 
Ainsworth et al.) 
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1972-
1977 
Detection of impaired synthesis of a marker for glycoprotein (lysosomal 
enzymes) routing as cause for a human disease (mucolipidosis II) and its 
identification as Man-6-phosphate, the ligand for P-type lectins (E. F. 
Neufeld and colleagues; W. S. Sly and colleagues) 
1974 Isolation of a mammalian Gal/GalNAc-specific lectin from the liver 
(G. Ashwell) 
1978 First conference focusing on lectins and glycoconjugates, termed Interlec 
(T. C. Bøg-Hansen) 
1979 Detection of endogenous ligands for plant lectins (H. Rüdiger) 
1983 Detection of the insecticidal action of a plant lectin (L. L. Murdock) 
1984 Isolation of lectins from tumors (H.-J. Gabius; R. Lotan, A. Raz) 
1985 Immobilized glycoproteins as pan-affinity adsorbents for lectins (H. Rüdiger) 
1987 Introduction of neoglycoconjugates for localization of tissue lectins to tumor 
diagnosis (H.-J. Gabius and colleagues) 
1989 Detection of the fungicidal action of a plant lectin (W. J. Peumans) 
1992/93 Detection of impaired synthesis of lectin (selectin) ligands by defective 
fucosylation as cause for leukocyte adhesion deficiency type II (A. Etzioni 
and colleagues) 
1995 Structural analysis of a lectin-ligand complex in solution by NMR 
spectroscopy (J. Jiménez-Barbero and colleagues) 
1996-  
1998 
Detection of differential conformer selection by plant and animal lectins 
(H.-J. Gabius and colleagues; L. Poppe and colleagues) 
2001/02 Advances in lectinology and glycosciences honored by devoting special 
issues in Biochim. Biophys. Acta, Biochimie, Biol. Chem., Cells Tissues 
Organs, Chem. Rev., Curr. Opin. Struct. Biol., J. Agric. Food Chem. (Liener 
symposium), and Science to the topics 
from Gabius et al. (2004) 55 
The definition of lectins has undergone some changes over time. Today, lectins are 
understood as carbohydrate-binding proteins, excluding carbohydrate-specific antibodies, 
enzymes modifying the structure of the carbohydrate ligand (substrate) and proteins 
accommodating free mono- or disaccharides (e.g. transport proteins or chemotaxis 
receptors) 56, 57, 58. The ability to distinguish blood group A from B with the agglutinin from 
Dolichos biflorus, the N-acetylation of the terminal D-galactose being the only difference 
between the two, gives us a first insight of the recognition capacity of lectins. Lagging behind 
the progress in plant lectins, research over the last decades have shown an enormous 
complexity in vertebrate lectins 56, 59, 60. The structural analysis of the folding pattern and 
architecture of the carbohydrate-recognition domain (CRD) has defined a classification 
system for animal lectins as shown in table 2. 
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Table 2. Current categories for classification of various animal lectins 
Family Structural Motif Carbohydrate Ligand Modular 
Arrangement 
C-type conserved CRD variable (mannose, 
galactose, fucose, heparin 
tetrasaccharide) 
Yes 
I-type immunoglobulin-like CRD variable (Man6GlcNAc2, 
HNK-1 epitope, hyaluronic-
acid, α2,3/α2,6-
sialyllactose) 
Yes 
Galectins 
(S-type) 
conserved CRD β-galactosides variable 
Pentraxins pentameric subunit 
arrangement 
4,6-cyclic acetal of 
β-galactose, galactose 
sulfated and phosphorylated 
monosaccharides 
Yes 
P-type homologous, not yet 
strictly defined CRD 
mannose-6-phosphate-
containing glycoproteins 
Yes 
from Gabius (2006) 61  
Having clarified structural aspects, it is pertinent to give a summary on current lectin 
functions. This is demonstrated in table 3, where numerous functions can be ascribed to a 
class of lectins. Animal lectins in general appear to have a wide variety of functions. 
Table 3. Functions of animal lectins 
Activity Example of Lectin 
Recognition of stem region of 
N-glycans, a signal for ubiquitin 
conjugation when accessible in 
incorrectly folded glycoproteins 
F-box proteins Fbs1/2 (Fbx2/FBG1, Fbx6b/FBG2) 
as a ligand-specific part of SCF ubiquitin ligase 
complexes 
Molecular chaperones with dual 
specificity for Glc1Man9GlcNAc2 and 
protein part of nascent 
glycoproteins in endoplasmic 
reticulum (ER) 
Calnexin, calreticulin 
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Targeting of misfolded 
glycoproteins with Man8-5GlcNAc2 
as carbohydrate ligand to ER-
associated degradation (ERAD) 
EDEM1,2/Mnl1 (Htm1) Yos9 protein (MRH domain) 
Intracellular routing of 
glycoproteins  
and vesicles and apical delivery  
ERGIC-53 and VIP-36 (probably also ERGL and 
VIPL), P-type lectins, comitin, galectin-4 
Intracellular transport and 
extracellular assembly 
Non-integrin 67 kDa elastin/laminin-binding protein 
Enamel formation and 
biomineralization 
Amelogenin 
Inducer of membrane 
superimposition and zippering 
(formation of Birbeck granules) 
Langerin (CD207) 
Cell type-specific endocytosis Hepatic and macrophage asialoglycoprotein 
receptors, dendritic cell and macrophage C-type 
lectins (mannose receptor family members) 
(tandem-repeat type) and single CRD lectins such 
as trimeric langerin/CD207 or tetrameric DC-
SIGN/CD209), cysteine-rich domain (β-trefoil) of 
the dimeric form of mannose receptor for GalNAc-
4-SO4-bearing glycoprotein hormones in hepatic 
endothelial cells, P-type lectins 
Recognition of foreign glycans 
(β1,3-glucans, LPS) 
CR3 (CD11b/CD18, Mac-1 antigen), C-type lectins 
such as DC-SIGN and dectin-1, immulectins, 
intelectins, Limulus coagulation factors C and G, 
earthworm CCF 
Recognition of foreign or aberrant 
glycosignatures on cells (incl. 
endocytosis or initiation of 
opsonization or complement 
activation) 
Collectins, ficolins, C-type macrophage and 
dendritic cell lectins, CR3 (CD11b/CD18, Mac-1 
antigen), α/Θ-defensins, pentraxins (CRP, limulin), 
tachylectins 
Targeting of enzymatic activity in  
multimodular proteins 
Acrosin, Limulus coagulation factor C, laforin 
(frequent in microbial glycosylhydrolases for plant 
cell wall polysaccharides) 
Bridging of molecules Galectins, cytokines (e.g. IL-2:IL-2R and CD3 of 
TCR), cerebellar soluble lectin 
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Induction or suppression of 
effector  
release (H2O2, cytokines, etc.) 
Galectins, selectins and other C-type lectins  
such as CD23, BDCA-2 and dectin-1, I-type lectins 
(CD33 (siglec-3), siglecs-7 and -9) 
Cell growth control, induction of 
apoptosis/anoikis and axonal 
regeneration 
Galectins, C-type lectins, amphoterin-like protein, 
hyaluronic-acid-binding proteins, cerebellar soluble 
lectin, CD22 (siglec-2), MAG (siglec-4) 
Cell migration and routing Galectins, selectins and other C-type lectins, I-type 
lectins, hyaluronic-acid-binding proteins  (RHAMM, 
CD44, hyalectans/lecticans) 
Cell-cell interactions Selectins and other C-type lectins  (e.g.  
DC-SIGN), galectins, I-type lectins  
(e.g. siglecs, N-CAM, P0 or L1), gliolectin 
Cell-matrix interactions Galectins, heparin- and hyaluronic-acid-binding 
lectins including hyalectans/lecticans, calreticulin 
from Gabius (2006) 61  
As mentioned above, spatial accessibility is a requirement for reading the sugar code. Units of 
β-galactose are located at the tips of glycan branches. Galectins are lectins with specificity for 
this sugar. They are often listed in table 3, showing that galectins influence numerous aspects 
of cell biology. This is seen in their contribution to cell adhesion, migration, growth control, 
effector release and immune regulation 42, 56, 62, 63, 64, 65. 
1.3 Galectins 
Galectins are a conserved family of β-galactosyl-binding lectins that occur in both vertebrates 
and invertebrates 66. They share binding activities towards β-galactosides and derivatives 
thereof and do not make use of any metal ion in their binding site  67. Structurally, the folding 
pattern is an antiparallel β-sandwich and named the legume-lectin-like β-sandwich, also 
known as the jelly-roll-like fold 68. The family of galectins have previously been known as the 
S-type (sulfhydryl-dependent) lectins, but the name of the family has changed, as a few 
family members are not sulfhydryl-dependent 69. The profiles of fine specificities of the 
individual galectins can differ to a certain extent, when testing a wide panel of synthetic and 
natural oligosaccharides, dendrimers or glycoproteins 70, 71, 72, 73, 74. To date, there are 14 
known family members of galectins in mammals. They have been grouped into three 
subfamilies: the proto-type, tandem-repeat-type and chimera-type galectins 75. The growth 
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regulation on human neuroblastoma cells by proto-type galectin-1 and its competitive 
inhibition by chimera-type galectin-3 clearly shows that galectins cannot simply be regarded 
as functional homologues, even when their ligand selection is very similar 76, 77. Here, 
functional divergence was seen between two galectins belonging to different subgroups. Is 
function related to subgroup classification? In a study by Sturm et al., the effects of three 
members of the proto-type family, galectins-1, -2 and -7, were determined on activated 
T cells 78. Intriguingly, the responses of the T cells differed with each of the tested galectins. 
This proves that despite the common specificity for β-galactosides, galectin functions can 
differ between subfamilies as well as within the same subfamily. The proto-type galectins are 
homodimers composed of subunits of approximately 130 amino acids. Each subunit folds as 
one compact jelly-roll-like globular domain 67, 79. The tandem-repeat-type galectins contain 
two homologous CRDs connected by a peptide linker 80. Galectin-3 is presently the only 
member defined as a chimera-type galectin. In addition to the CRD, galectin-3 has a short N-
terminal domain and an intervening proline, glycine and tyrosine-rich domain. Galectin-3 is 
isolated as a monomer but undergoes multimerization on binding to surfaces that contain 
multivalent glycoconjugate ligands, and the N-terminal half of the protein is required for this 
property 81, 82, 83. An important consequence of the galectin structures described above is that 
most are topologically multivalent, either by forming non-covalent dimers or higher 
oligomers, or by having two CRDs within one peptide chain. They are therefore able to cross-
link β-galactoside containing glycoconjugate ligands at physiological concentrations, possibly 
resulting in modulation of cell adhesion and signaling 62, 84, 85, 86. A list of mammalian 
galectins, their occurrence in cells and tissues, and their structural features is given in table 4. 
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Table 4. Members of the galectin family. From Gabius (2006) 61. 
Name Occurrence Structural Features 
galectin-1 
(galaptin, L-14) 
many cell types homodimer; one CRD per subunit 
(14-15 kDa): proto-type 
galectin-2 predominantly epithelial 
presence in digestive, 
pulmonary and urogenital 
tracts 
homodimer; one CRD per subunit 
(43% sequence identity to 
galectin-1; 14 kDa): proto-type 
galectin-3 (CBP35, 
Mac-2 antigen, IgE-
binding protein, 
L-29, L-34) 
many cell types monomer with one CRD (pentamer 
formation in solution and on 
surfaces); pro-, tyr-, and gly-rich 
repeats in N-terminal section 
(27-36 kDa): chimera-type 
galectin-4 colon, small intestine, 
stomach, oral epithelium, 
esophagus, lung, testis, 
breast, liver and placenta by 
RT-PCR 
monomer with two partially 
homologous but distinct CRDs, 
connected by a link peptide 
(36 kDa); proteolysis generates 
truncated proto-type-like 
products: tandem-repeat-type 
galectin-5 Reticulocytes, erythrocytes 
(rat) 
monomer with one CRD  
(17 kDa): proto-type 
galectin-6 small intestine, colon (mouse) tandem-repeat arrangement  
of two CRDs (33 kDa) 
galectin-7 keratinocytes, stratified 
epithelia, carcinoma cells 
homodimer; one CRD per subunit 
(15 kDa): proto-type 
galectin-8 several tissues; frequent 
presence in tumor cell lines 
(link peptide extension 
possible) 
homologous to galectins-4 and -6 
(tandem-repeat arrangement of 
two CRDs with unique link 
peptide; 34 kDa) 
galectin-9 small intestine, liver, lung, 
kidney, thymus (rat/mouse; 
small intestinal isoform with 
31/32 amino acid extension 
of link peptide); lymphatic 
tissue and B cells, T cells and 
macrophages, pancreas, 
colon carcinoma cells  
(human) 
homologous to galectins-4, -6 and 
-8 (tandem-repeat arrangement of 
two CRDs with unique link 
peptide; 36 kDa) 
Charcot-Leyden 
crystal protein 
(galectin-10) 
major autocrystallizing 
constituent of eosinophils  
and basophils 
One CRD-like structure with 
specificity to D-Man (16.5 kDa) 
galectin-11 
(ovgal-11) 
sheep gastrointestinal tract, 
induced upon nematode 
infection 
One CRD resembling proto-type 
galectins (14 kDa) 
galectin-12 several tissues (upregulation 
in cells synchronized at the G1 
phase or G1/S boundary of 
the cell cycle), adipocytes 
homologous to galectins-4, -6, -8 
and -9 (tandem-repeat 
arrangement of two CRDs with 
unique link peptide; 35.3 kDa) 
galectin-13 identical to placental protein 
13 (pp13); also expressed in 
spleen, kidney, bladder and in 
tumor cells 
homodimer; one CRD per subunit 
(16.1 kDa); close similarity to 
galectin-7 and the Charcot-Leyden 
crystal protein 
galectin-14 ovine eosinophils, secreted 
into bronchoalveolar lavage 
fluid 
one CRD resembling proto-type 
galectins (18.2 kDa) 
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Many of the functions of galectins described above are sugar-dependent. It is interesting to 
note that galectins can also target peptide and lipid moieties 87, 88. This presents additional 
possibilities of interacting with binding partners and associated effects. Table 5 gives a 
summary of known physiologically relevant binding partners for galectins-1 and -3 grouped 
by the type of interaction. 
Table 5. Binding Partners for Galectins-1 and -3.  
Type of ligand Galectin-1 Galectin-3 
Glycan  CA125, CD2, CD3, CD4, CD7, 
CD43, CD45, CEA, fibronectin 
(tissue), GI mucin, hsp90-like 
glycoprotein, α1/α5/α7/β1-
integrins, L1, laminin, lamp-1, 
Mac-2 binding protein, 
thrombospondin, Thy-1, 
chondroitin sulfate proteoglycan, 
distinct neutral glycolipids, 
ganglioside GM1 
 
LI-cadherin, C4.4A (member of 
Ly6 family), IgE, CD7, CD11b of 
CD11b/CD18 (Mac-1 antigen, 
CR3), CD32, CD66a,b, CD95, 
CD98, CEA, colon cancer mucin, 
cubilin, haptoglobin β-subunit 
(after desialylation), hensin 
(DMBT-1), β1-integrin (CD29), 
laminin, lamp-1/-2, Mac-2 
binding protein, Mac-3, MAG, 
MP20 (tetraspanin), NG2 
proteoglycan, TCR complex, 
tenascin, ganglioside GM1 
protein  Gemin4, oncogenic H-Ras, pre-B 
cell receptor (human, not murine 
system) 
AGE products, Alix/AIP-1, axin, 
Bcl-2, β-catenin, Cys/His-rich 
protein, Gemin4, mSufu, nucling, 
oncogenic K-Ras, pCIP, PIAS1, 
synexin (annexin VII), TTF-1 
from Gabius (2006) 61 
As shown in table 4, in which each galectin member is assigned to one of the three subgroups, 
proto-type galectins are well established with several members. It is an open question whether 
the close structural similarity (see below) will translate into functional overlap when 
overexpressed in cells. 
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1.4 Proto-Type Galectins-1, -2 and -7 
These three galectins are of particular interest, because of their structural similarities, their 
reported growth inhibitory effects and also because of reported functional divergence seen 
after exogenous addition to activated T cells 78. In addition to the information given in table 4 
on occurrence and basic structural features of the proto-type galectins-1, -2 and -7, 
comparative structural aspects will be discussed. Alignment of amino acid sequences of the 
human galectins-1, -2 and -7 is shown in figure 1. The identity scores between gal-1 and -2 
are highest with 43 %. Comparison of gal-1 and gal-7 results in 31 % identity, and gal-2 and 
gal-7 show the least number of common amino acids among the three galectins with 26 % 
identity. 
1                                                   50 
hGal-1   MACGLVASNL ..NLKPGECL RVRGEVAPDA KSFVLNL... GKDSNNLCLH 
hGal-2   MTGELEVKNM ..DMKPGSTL KITGSIADGT DGFVINL... GQGTDKLNLH 
hGal-7   MSNVPHKSSL PEGIRPGTVL RIRGLVPPNA SRFHVNLLCG EEQGSDAALH 
Consensus  M...l..sn$ ....kPG..L r!rG.!ap.a ..Fv.NL... g.....l.LH 
 
51                                                 100 
hGal-1   FNPRFNAHGD ANTIVCNSKD GGAWGTEQRE AVFPFQPGSV AEVCITFDQA 
hGal-2   FNPRFSE... .STIVCNSLD GSNWGQEQRE DHLCFSPGSE VKFTVTFESD 
hGal-7   FNPRLDT... .SEVVFNSKE QGSWGREERG PGVPFQRGQP FEVLIIASDD 
Consensus FNPRf..... .st!VcNSk# gg.WG.E#Re ...pFqpGs. .ev.!tf..d 
 
101                                       141 
hGal-1   NLTVKLPDGY EFKFPNRLNL EAINYMAADG DFKIKCVAFD . 
hGal-2   KFKVKLPDGH ELTFPNRLGH SHLSYLSVRG GFNMSSFKLK E 
hGal-7   GFKAVVGDAQ YHHFRHRLPL ARVRLVEVGG DVQLDSVRIF . 
Consensus .fkvklpDg. e..FpnRL.l ....y..v.G df...sv... . 
Figure 1. Sequence comparison of human galectins-1, -2 and -7. Amino acid sequences of human 
gal-1, -2, and -7 were aligned using the program Multalin version 5.4.1 (http://prodes.toulouse.inra.fr/ 
multalin/multalin.html). A consensus sequence calculated from the three galectin sequences is added 
to the alignment; consensus symbols represent: ! is I or V; and # is N, D, Q, or E. 
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The structures of galectins-1, -2 and -7 have been determined by X-ray crystallography. These 
studies revealed that the CRD is folded tightly, with two anti-parallel β-pleated sheets 
forming a sandwich-like structure 89. Amino acid side chains on one of these sheets form the 
core carbohydrate-binding site. Pictures of the X-ray crystal structures are displayed in 
figures 2 to 4.  
 
Figure 2. X-ray crystal structure of a galectin-1 homodimer complexed with Gal-β1,4-Glc 90 
(PDB code 1GZW). 
Having illustrated the structural details of the three proto-type galectins-1, -2 and -7, their 
relation to clinical aspects, especially cancer, will be given in the next chapter.  
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Figure 3. X-ray crystal structure of a galectin-2 homdimer complexed with Gal-β1,4-Glc 67 
(PDB code 1HLC). 
 
Figure 4. X-ray crystal structure of a galectin-7 homodimer complexed with Gal-β1,4-GlcNAc 91 
(PDB code 5GAL). 
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1.5 Galectins in Cancer 
Adenocarcinoma of the large bowel affects one person in 20 in most Westernized countries 92. 
More than 155,000 new cases are diagnosed in the United States each year, representing 15 % 
of all cancers. This disease clearly constitutes a major public health problem, and improved 
disease management can be expected from advances in understanding of the malignant 
phenotype. 
Malignant transformation of cells is often caused by molecular defects, which consist of 
mutations in key classes of genes governing cell growth 65. These mutations alter the amount 
or behavior of the proteins encoded by proliferation-regulating genes and thereby disrupt 
functions that control cell division. Members of the galectin family have been proposed to 
mediate cell adhesion, to regulate cell growth, and to trigger or inhibit programmed cell death. 
It has been demonstrated that the expression pattern of various galectins is altered in 
carcinomas. Summarizing the current status, it is fair to say that galectins are expressed in 
tumors heterogeneously, as also known from other markers 93. The clinical significance of 
heterogeneity is currently not defined and calls for rigorous examination in suitable cell 
biological models. This issue has given research a clear direction which will be discussed 
below, after providing details to the significance of galectin presence in malignancy. 
Focusing on the proto-type family members, studies have shown galectins as key factors in 
malignancies of neoplasms including colon cancer 94. Studies have shown higher levels of 
galectin-1 in colon neoplasm in comparison to the normal mucosa, and have also correlated 
overexpression with advanced tumor stages and shorter survival 95. Nagy et al. have also 
recognized galectin-1 as a prognostic factor in colon tumors, which had been classified as 
Dukes A and B tumors 96. High levels of galectin-1 were inversely correlated with survival 
periods. Using Northern blotting and Western blotting analysis, in situ hybridization and 
immunohistochemistry, Berberat et al. have investigated the expression pattern of galectin-1 
in primary pancreatic cancers and in metastases in comparison to normal pancreases 97. They 
observed a strong galectin-1 immunoreactivity in most fibroblasts in fibrotic tissue strains in 
and around the tumor mass. However, no labeling was found for galectin-1 in metastatic 
pancreatic cells. 
Less data is available concerning the expression of other proto-type galectins such as 
galectins-2 and -7 in malignancy. In a study by Saal et al., galectin-2 and galectin-2 binding 
sites were visualized in histological tissue samples of various origin, including normal tissue 
and samples with benign/malignant neoplasms98. A tendency of increased presentation of 
galectin-2-binding sites was seen in malignant tissue. Polyak et al. have identified the 
Introduction 
 
17 
transcription of the galectin-7 gene to be upregulated before the onset of p53-induced 
apoptosis in DLD-1 colon cancer cells 99. Apparently, galectin-7 functions as a proapoptotic 
factor, as has been recognized in studies by Kuwabara et al. 100. This makes recent findings of 
Saussez et al. particularly interesting, in which high levels of galectin-7 has been positively 
correlated to a high recurrence rate and poor prognosis of stage IV hypopharyngeal cancer 101. 
Galectin-7 has therefore been related to effects beneficial for prognosis (proapoptotic activity) 
and unfavorable prognosis (clinical correlation). 
Turning to cancer cell lines as an in vitro model to investigate characteristics of tumor cells, a 
study by Lahm et al. was conducted with a panel of 61 tumor cell lines of different origin 102. 
The expression patterns for human galectins-1, -2, -3, -4, -7, -8, and -9 were defined by using 
the RT-PCR approach. This study was designed as fingerprinting, without detailed functional 
investigation. Its strength is the fact that it identified cancer cell lines, which lack expression 
of certain proto-type galectins. These data will thus provide a guideline to select colon cancer 
lines for a study on ectopic expression of proto-type galectins-1, -2 and -7. Explicitly, the 
lines HCT-15 and DLD-1 appeared to be suitable to examine the effects of overexpression of 
galectins-1, -2, and -7 on clinically relevant cell behavior. This reasoning guides to the 
objectives of the thesis.  
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2 Objectives 
• to establish stable clones of cell transfectants with ectopic galectin overexpression in 
the cases of the three homodimeric proto-type galectins 
• to select subclones with different extent of galectin expression on the basis of 
biochemically monitoring protein presence 
• to determine cell surface expression by FACS analysis 
• to monitor intracellular expression and nuclear presence by immunocytochemical 
analysis 
• to monitor morphological aspects by videomicroscopy 
• to determine the effect of lectin expression on anchorage-independent growth 
• to determine the effect of lectin expression on anchorage-dependent growth 
• to determine the effect of lectin expression on the doubling time 
• to determine the effect of lectin expression on growth in medium with reduced content 
of nutrients 
• to determine the effect of lectin expression on sensitivity to chemotherapeutics 
• intergalectin comparison of the data sets obtained from the three different proto-type 
galectins 
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3 Materials, Methods and Equipment 
3.1 Materials 
Chemicals and other materials were purchased from Carl Roth GmbH & Co. KG, Karlsruhe, 
VWR International GmbH, Ismanning and from Sigma, Munich and were of analytical grade. 
It is indicated if chemicals or other materials were used from other sources. 
Agarose SeaKem LE agarose             
(Product No. 50004) 
BioWhittaker Molecular Applications, 
Rockland, Maine, U.S.A. 
Bio-Rad protein assay dye reagent 
concentrate 
Bio-Rad Laboratories GmbH, Munich, 
Germany 
CL-Xposure film (Product No. 34090) Perbio Science Deutschland GmbH, Bonn, 
Germany 
Coverslips (sterile) Superfrost Menzel GmbH & Co. KG, Braunschweig, 
Germany 
Diethylpyrocarbonate (DEPC) AppliChem GmbH, Darmstadt, Germany 
D-lactose monohydrate (Product No. 61340) Fluka Chemie, Buchs, Switzerland 
DMEM/F-12 (1:1) powder                 
(Product No. 42400-010) 
Gibco BRL, Life Technologies, Invitrogen 
GmbH, Karlsruhe, Germany 
DNA extraction kit  Wizard Genomic DNA Purification Kit, 
Promega GmbH, Mannheim, Germany 
DNA loading dye solution, 6 x Fermentas GmbH, St. Leon-Rot, Germany 
ECL Western blotting detection reagents Amersham Biosciences Europa GmbH, 
Freiburg, Germany 
ELISA microplate, MICROLON 600, 
96-well, high binding, U-bottom  
Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Eukaryotic expression vector pCDNA3.1(+) Invitrogen, Karlsruhe, Germany 
Fetal calf serum (Product No. S0115) Biochrom, Berlin, Germany 
GeneRuler 100 bp DNA ladder plus Fermentas GmbH, St. Leon-Rot, Germany 
Methylcellulose (Product No. 64630) Methocel MC, viscosity 4,000 mPa.s, Fluka 
Chemie, Buchs, Switzerland 
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Nunclon ∆ 60 mm dishes, gridded 2 x 
2 mm, for selection of clones 
Nunc GmbH & Co. KG, Wiesbaden, 
Germany 
o-Phenylenediamine dihydrochloride (OPD) 
(Product No. 78440) 
Fluka Chemie, Buchs, Switzerland 
PROTRAN nitrocellulose transfer 
membrane, pore size 0.2 µm 
Schleicher & Schuell GmbH, Dassel, 
Germany 
Petri dish with vents, 35 mm Greiner Bio-One GmbH, Frickenhausen, 
Germany 
Plasmid isolation Perfectprep Plasmid Midi (Eppendorf, 
Hamburg, Germany) 
Poly-L-lysine hydrobromide 30,000-70,000 
(Product No. 81338) 
Fluka Chemie, Buchs, Switzerland 
Reverse Transcriptase Superscript II 
RNase H- 
Invitrogen/Life Technologies, Karlsruhe, 
Germany 
RNA isolation, RNeasy Mini Kit Qiagen, Hilden, Germany 
G418 sulfate (Product No. 345810) Calbiochem, EMD Biosciences, Inc, 
Darmstadt, Germany 
Tetramethylethylenediamine (TEMED) Serva, Heidelberg, Germany 
Thiazolyl Blue Tetrazolium bromide (MTT) 
(Product No. 88415) 
Fluka Chemie, Buchs, Switzerland 
Tissue culture flask, 25 cm2 style, 50 ml Falcon, Becton Dickinson U.K. LTD, 
Plymouth, England 
Transfection Reagent SuperFect Qiagen, Hilden, Germany 
Tissue culture test plates 96-well, well ∅ 
6.7 mm; 24-well, ∅ 16.2 mm; 12-well, 
∅ 22.2 mm; 6-well, ∅ 34.5 mm, flat 
bottom 
TPP AG, Trasadingen, Switzerland 
Triton X-100  Serva, Heidelberg, Germany 
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3.2 Equipment 
Autoclave steam sterilizer Varioklav, H + P Labortechnik GmbH, 
Oberschleißheim 
Biological safety cabinet Microflow Class 2, Nunc GmbH & Co. KG, 
Wiesbaden, Germany 
Centrifuge, Eppendorf  5415 C , Eppendorf AG, Hamburg, Germany 
Centrifuge, Hettich EBA 3 S  Hettich, Tuttlingen, Germany 
Centrifuge, Refrigerated Z382K, Hermle Labortechnik GmbH, Wehingen, 
Germany 
CO2 incubator Cellstar, Nunc, Nalge Nunc International, Rochester, 
NY, U.S.A. 
Dry heat sterilizer Memmert model no. 500, Memmert GmbH & Co. 
KG, Schwabach, Germany 
Flow cytometer FACScan and CellQuest software, Becton Dickinson, 
BD Biosciences, San Jose, CA, U.S.A. 
Gel documentation Gel Doc 2000 Software: Quantity One 4.1.1, Bio-Rad 
Laboratories GmbH, Munich, Germany 
Inverted optical microscope Wilovert S, Wetzlar, Germany 
Isopropanol freezing container NALGENE Cryo 1 C Freezing Container, Nunc, 
Nalge Nunc International, Rochester, NY, U.S.A. 
Mechanic tissue homogenizer Ultra-Turrax T25 with dispersing tool S25N-8G, 
Janke & Kunkel, Staufen, Germany 
Microcentrifuge 5415 D, Eppendorf AG, Hamburg, Germany 
Microplate reader Model 550, Bio-Rad Laboratories GmbH, Munich 
Germany 
Microscope Olympus BH-2, Olympus Deutschland GmbH, 
Hamburg, Germany 
Microwave Model M633, Samsung, Korea 
Photometer Hitachi U-2000 Spectrophotometer, Colora 
Messtechnik GmbH, Lorch, Germany 
Power supply Power Pac 3000, Bio-Rad Laboratories GmbH, 
Munich, Germany 
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Rotator Roto-Torque, Model No. 7637-10, Cole-Parmer 
Instrument Company, Vernon Hills, Illinois, USA 
Scanner Coolscan 5000, Nikon GmbH, Düsseldorf, Germany 
SDS-PAGE protein sequestration 
Equipment 
Mini-PROTEAN II cell, Bio-Rad Laboratories 
GmbH, Munich, Germany 
Shaker Ika-Vibrax-VXR, IKA-Werke GmbH & Co. KG, 
Staufen, Germany 
Ultrasonic homogenizer Sonopuls GM 200, Sonotrode MS73, Bandelin 
electronic, Berlin, Germany 
Water heater Thermostat 2761, Eppendorf AG, Hamburg, 
Germany 
Western blotting apparatus Bio-Rad Mini Trans-Blot Electrophoretic Transfer 
Cell, Bio-Rad Laboratories GmbH, Munich, 
Germany 
 
3.3 Cell Culture 
3.3.1 Cell Lines 
HCT-15 epithelial, colorectal adenocarcinoma, CCL-225, American Type Culture 
Collection 
DLD-1 epithelial, colorectal adenocarcinoma, CCL-221, American Type Culture 
Collection 
3.3.2 Cell Culture Conditions 
Both cell lines were grown in RPMI-1640 medium (Sigma, R-6504), supplemented with 
2 mM L-glutamine (Sigma, G-8540), 100 U/ml penicillin G sodium salt (Sigma, P-3032) and 
100 µg/ml streptomycin sulfate (Sigma, S-9137). In general, 10 % of FCS (v/v) that had been 
heat inactivated for 30 min at 56 °C was added. Content of FCS was only reduced for specific 
assays of growth characteristics with reduced content of FCS. 
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Cells were kept at constant conditions in an incubator, with a temperature of 37 °C and 5 % 
CO2 in the humidified atmosphere. Unless specified, cells were grown in 25-cm2-style (50 ml) 
sterile tissue culture flasks with 5 to 7 ml culture medium, depending on cell density. To 
enable gas exchange, the cap was screwed on loosely. Culture medium was exchanged after 4 
days or when the phenol red pH indicator in the medium turned to a yellowish bright orange, 
showing an increase in acids resulting from the cells metabolizing the nutrients in the 
medium.  
3.3.3 Passaging of Cells 
20 mM phosphate-buffered saline (PBS), pH 7.2: 
Stock solution A (1 x: 1.54 M NaCl, 20 mM Na2HPO4 x 2 H2O) 10 x:  
90 g NaCl 
35.6 g Na2HPO4 x 2 H2O 
aqua dest. ad 1,000 ml 
Stock solution B (1 x: 1.5 M NaCl, 0.1 M KH2PO4) 10 x: 
87.7 g NaCl 
13.6 g KH2PO4 
aqua dest. ad 1,000 ml 
Eighty milliliters of stock solution A and 20 ml of stock solution B were mixed and then 
diluted with aqua dest. to a volume of 1,000 ml to obtain a 20 mM phosphate-buffered saline 
solution, pH 7.2. 
PBS-EDTA-detaching solution: PBS was supplemented with 2 mM EDTA disodium 
dihydrate, 0.75 g/l, and the pH was set to 7.2. The solution was autoclaved and stored at 4 °C. 
Before the cells grew to a confluent layer, which might then acquire different properties 
resulting from density dependent growth inhibition, the cell number in the flask was reduced 
by detaching the cells using 2 ml of 20 mM PBS pH 7.2 containing 2 mM EDTA. After 5 min 
of incubation, the loosely attached cells were brought into suspension first by gently pushing 
the flask against the palm of the left hand and then by repeatedly pipetting the cell suspension 
and washing off cells of the bottom of the flask. The cells were then first transferred to and 
later centrifuged in sterile centrifuge tubes at 2,000 rpm (Hettich centrifuge) for 3 min to form 
a cell pellet from which the supernatant could easily be removed. Afterward, cells were 
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resuspended in culture medium. A fraction of the volume was transferred back into the tissue 
culture flask, and additional medium was added as necessary.  
3.3.4 Generation of Stable Cell Transfectants 
LB-Medium: 
25 g Luria Bertani Broth base (Roth, Product No. X968.1) 
ad 1,000 ml aqua dest., pH 7.2 
autoclaved and stored at 4 °C 
Plasmid preparation: Perfectprep Plasmid Midi (Eppendorf, Hamburg, Germany) 
Stable cell transfectants were generated as previously described 103, 104, 105. The vectors for 
transfection of the cell lines were provided by our laboratory. In order to clone and amplify 
DNA sequences encoding human full-length galectin-1 cDNA (408 bp), galectin-2 cDNA 
(399 bp) or galectin-7 cDNA (411 bp) that were suitable for ligation into the Kpn I restriction 
site of the eukaryotic expression vector pcDNA3.1(+), a PCR reaction was performed with 
the following primer sets (the Kpn I restriction site is underlined): 
Table 6. Primers used for PCR of human full-length galectin-1-, galectin-2- and galectin-7-cDNA 
suitable for ligation into the expression vector pcDNA3.1(+). The Kpn I restriction site is underlined.  
gal-1 forward 5’-CGCTAGGGTACCATGGCTTGTGGTCTGGTCG-3’ 
gal-1 reverse 5’-CGTACGGGTACCTCAGTCAAAGGCCACACA-3’  
gal-2 forward 5’-CGTACGGGTACCATGACGGGGGAACTTG-3’ 
gal-2 reverse 5’-CGCTAGGGTACCTTATTCTTTTAACTTGAAAGAGGACATG-3’ 
gal-7 forward 5’-CGTACGGGTACCATGTCCAACGTCCCC-3’ 
gal-7 reverse 5’-CGTTAGGGTACCTCAGAAGATCCTCACG-3’ 
The cDNA preparations for galectins-1, -2 or -7 were then subcloned into the Kpn I restriction 
site of the eukaryotic expression vector pcDNA3.1(+), where the respective galectin-specific 
cDNA was under control of the CMV promoter and clones could be selected by neomycin 
resistance. The ATG start codon was positioned into a Kozak translation initiation sequence 
(…ANNATGG…) for proper initiation of translation. The three vectors pcDNA3.1Gal-1, 
pcDNA3.1Gal-2 and pcDNA3.1Gal-7 were transformed into the E. coli strain TOP10 
(Invitrogen, Karlsruhe, Germany). Isolated plasmids obtained from propagated single colonies 
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were screened for sense/antisense orientation by PCR. E.coli TOP10 bacteria containing 
plasmids with the respective galectin-specific cDNA in sense orientation were grown in 50 ml 
LB medium overnight. The plasmids for the transfection experiments were prepared using 
Perfectprep Plasmid Midi (Eppendorf, Hamburg, Germany). Agreement with databank 
sequences and in frame cloning were ascertained by sequencing (GATC, Konstanz, 
Germany). For the transfection experiments, the vectors were linearized with the restriction 
enzyme Bgl II.  
Transfections were done using SuperFect Transfection Reagent (Qiagen), which generated 
liposome complexes. For stable transfections, 2 µg plasmid DNA and 10 µl SuperFect reagent 
were incubated in 100 µl serum- and antibiotic-free medium for 10 min at room temperature 
to allow complex formation. Sixty thousand cells were seeded the day before transfection in a 
35 mm dish (6-well plate) to lead to 60 to 80 % confluence on the day of transfection. While 
complex formation took place, the growth medium was aspirated from the dish and washed 
once with 4 ml 20 mM PBS, pH 7.2. One milliliter of growth medium (containing serum and 
antibiotics) was added to the reaction tube containing the transfection complexes. After 
mixing, the medium was transferred to the cells in 35 mm dishes. The cells were incubated 
with the complexes for 3 h at 37 °C and 5 % CO2. The medium containing the remaining 
complexes from the cells was carefully aspirated, and the cells were washed four times with 
4 ml of 20 mM PBS, pH 7.2. Fresh cell growth medium was added, and the cells were 
incubated for 48 h. After trypsinization, resuspended cells were seeded into three 6 cm dishes 
and selection was performed with G418 (750 µg/ml) for 2 weeks. As control, the vector 
pcDNA3.1(+) without insert (mock treatment) was used to generate controls of stably mock-
transfected clones.  
3.3.5 Origin of Cell Clones 
The next task was to pick clones based on expression levels. Stably transfected cells were 
trypsinized, then one tenth of the suspension of cells was transferred into each of three 60 mm 
gridded Petri dishes. After 24 hours the cell population in the Petri dishes were examined 
under an invertoscope. Single adherent cells with sufficient distance to other cells, which 
might otherwise grow together, were localized and marked by drawing a circle around them 
on the bottom side of the Petri dish with a permanent marker. The Petri dishes were then 
placed in the incubator for an additional four to seven days until small colonies were visible. 
Following a subsequent examination using the invertoscope, suitable colonies - originating 
from single cells - that had not grown together with other neighboring colonies and were also 
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sufficiently distant from other colonies to ensure accurate picking of cells solely from this 
colony, were marked with a different colored marker on the bottom side of the Petri dish.  
A 96-well tissue culture test plate was prepared by adding 100 µl of selection medium to each 
well. The colonies that had been selected in the previous step were carefully picked by 
aspirating 10 µl with a pipette while pushing the tip of the pipette directly into the marked 
area against the bottom of the dish. The aspirated cells were put into the tissue culture test 
plate, one well for each of the picked colonies. Stable clones were cultivated in the presence 
of G418 (200 µg/ml) to ensure continued presence of resistance. 
Once the cells had nearly grown to confluence, they were detached with 20 µl of 20 mM PBS 
(pH 7.2) containing 2 mM EDTA and transferred to the wells of a 24-well cell culture plate 
containing 1 ml of selecting growth medium. The cells were then placed in the incubator until 
there was a sufficient quantity of cell material to biochemically assay the expression levels of 
the respective galectin. This was done by means of SDS-PAGE and subsequent Western 
blotting, ELISA and FACS analyses. 
3.3.6 Counting Cells 
Detaching solution: Trypsin-EDTA solution, 10 x (Sigma, T-4174) 
Important exception: no trypsin was used to detach the cells for the cell count prior to FACS 
or cytochemical analyses. FACS and cytochemical analyses are used to determine the 
presence of distinct proteins on the cell surface. Treatment of cells with trypsin can degrade 
cell surface proteins, thereby altering the results of these assays. 
Cells were washed once with 20 mM PBS, pH 7.2 and then incubated with the detaching 
solution for 5 min at 37 °C. The cells were suspended by repeatedly pipetting the solution 
against the bottom of the cell plate. A coverslip was placed onto an Improved Neubauer 
hemocytometer, and an aliquot of 10 µl was transferred to the cell counting chamber after 
mixing the cell suspension by pipetting the volume up and down. Four 1 mm squares were 
counted, and the average cell number per 1 mm2 was multiplied with the dilution factor and 
with 104, resulting in an estimation of the cell count per ml cell suspension. An average of at 
least four cell counts was used for further calculations. 
3.3.7 Freezing Cells 
Freezing medium: 45 % RPMI-1640 medium (v/v), 45 % FCS (v/v), 10 % DMSO (v/v) 
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Cells were detached with 20 mM PBS, pH 7.2 containing 2 mM EDTA, centrifuged at 
2,000 rpm (Hettich centrifuge), the supernatant was discarded, and the cells were washed 
once with 20 mM PBS, pH 7.2. After another round of centrifugation under the same 
conditions, the cells of the pellets were resuspended in freezing medium and filled in cryo-
vials as 1 ml aliquots, then placed in a container for freezing cells (NALGENE) filled with 
isopropanol to reduce the cooling speed to approximately 1 °C per minute. The container was 
placed in a -80 °C freezer overnight after which the cryo-vials were transferred to a liquid 
nitrogen storage tank. 
3.3.8 Thawing Cells 
Cryo-vials were placed in a water bath of 37 °C just until the ice in the vials melted. The cell 
suspension was then immediately transferred to a centrifuge tube with 4 ml of ice-cold 
RPMI-1640 medium. After centrifugation at 2,000 rpm (Hettich centrifuge) for 3 min, the 
supernatant was discarded and the cell pellet was resuspended in RPMI-1640 medium 
containing FCS, antibiotics and L-glutamine and then transferred to cell culture flasks. 
3.4 Biochemical Methods 
3.4.1 Preparation of Cell Lysates for SDS-PAGE Analysis 
Cell lysis buffer for SDS-PAGE of cellular extracts, pH 7.2: 
2 mM EDTA disodium dihydrate   0.075 g  
1 % Triton X-100 (v/v)   1 ml 
0.1 % sodium deoxycholate (w/v)   0.1 g 
50 mM D-lactose monohydrate  1.8 g 
2 mM DTT      0.031 g 
2 µg/ml aprotinin    200 µg 
5 µg/ml leupeptin    500 µg 
1 mM pefablock    0.024 g 
20 mM PBS, pH 7.2     ad 100 ml 
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Protein assay dye:  
Bio-Rad protein assay dye concentrate diluted 1:2.5 (40 % (v/v)) with aqua dest. 
Cells were detached and centrifuged as described and washed with 1 ml of cold 20 mM PBS, 
pH 7.2. After an additional centrifugation for 3 min at 800 x g (3,000 rpm, eppendorf 
centrifuge), the supernatant was removed. The cells were resuspended in cell lysis buffer for 
SDS-PAGE of cellular extracts. 50 µl of cell lysis buffer were added to cells grown to 
subconfluency in one well of a 24-well cell culture test plate. Two hundred microliters were 
added to cells from a tissue culture flask. The cells were further lysed using a homogenizer 
emitting ultrasonic waves in cycles of 90 % for 20 sec. During this procedure the suspension 
was cooled on ice to prevent overheating. The solution was centrifuged at 25,000 x g 
(14,000 rpm, Hermle centrifuge) and 4 °C for 5 min. The supernatant was transferred to a 
fresh mico-test tube, whereas the pellet was discarded.  
The protein content was determined using the method developed by Bradford 106 and adapted 
by Redinbaugh and Cambell for small volumes 107. A one microliter aliquot of cell extract was 
diluted with 20 mM PBS, pH 7.2 to 100 µl, and a series of concentrations was set up in a 
96-well plate by stepwise 1:2 dilutions. One microliter of lysis buffer plus 99 µl 20 mM PBS, 
pH 7.2, was used as blank to monitor the response of the assay without protein. One hundred 
microliters of 40 % commercial solution with protein assay dye was added to the wells. After 
an incubation time of 5 min at room temperature the optical density was determined at the 
wavelength of 595 nm using an ELISA minireader. Optical densities in the linear range 
between 0.4 and 0.6 were used to calculate the protein concentration relative to a standard 
curve established with BSA. 
3.4.2 SDS-PAGE 
10 % SDS (w/v): 10 g SDS, aqua dest. ad 100 ml, stored at room temperature 
Tris buffer, 0.5 M, pH 6.8: 6.06 g Tris-base, aqua dest. ad 100 ml, pH 6.8 
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SDS Sample buffer: 
3.8 ml aqua dest. 
1 ml 0.5 M Tris-HCl, pH 6.8 
0.8 ml glycerol 
1.6 ml SDS, 10 % 
0.4 ml β-mercaptoethanol 
0.4 ml 0.05 % bromophenol blue (w/v)  
stored at -20 °C 
Running Gel Tris Buffer (1.5 M Tris, 0.4 % SDS (w/v)), pH 8.8: 
45.4 g Tris-base 
1 g SDS 
aqua dest. ad 250 ml, pH 8.8, stored at 4 °C 
Stacking Gel Tris Buffer (0.5 M Tris, 0.4 % SDS (w/v)), pH 6.8: 
6.06 g Tris-base 
400 mg SDS 
aqua dest. ad 100 ml, pH 6.8, stored at 4 °C 
10 % ammonium persulphate (APS) (w/v): 
100 mg APS 
aqua dest. ad 1 ml, prepared just before use 
Rotiphorese Gel 30 (Roth, 3029.1): water soluble 30 % acrylamide (w/v) stock solution with 
0.8 % bis-acrylamide (w/v) 
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per Gel with a width of 1 mm: 
Stacking gel: acrylamide concentration 4 % (w/v) 
aqua dest.    1.55 ml 
0.5 M Tris, 0.4 % SDS, pH 6.8 625 µl 
Rotiphorese Gel 30   325 µl 
TEMED    4.5 µl 
10 % APS (w/v)   20 µl 
mixed together just prior to use 
Resolving gel: acrylamide concentration 15 % 
aqua dest.    1.8 ml 
0.5 M Tris, 0.4 % SDS, pH 6.8 1.7 ml 
Rotiphorese Gel 30    3.5 ml 
TEMED    6 µl 
10 % APS (w/v)   35 µl 
mixed together just prior to use 
Tris-glycine 10 x stock solution (250 mM Tris, 2 M glycine): 
30.3 g Tris 
150 g glycine  
aqua dest. ad 1,000 ml, stored at room temperature 
Electrophoresis buffer, 1 x: 
35 ml Tris-glycine 10 x stock solution 
3.5 ml 10 % SDS 
aqua dest. ad 350 ml, prepared just before use 
Recombinant galectins-1, -2 and -7, purified by affinity chromatography were supplied by our 
laboratory. 
One-dimensional discontinuous gel electrophoresis in the presence of SDS was essentially 
performed as first described by Laemmli 108. The samples were prepared by heating 50 µg of 
total protein with an equivalent amount of SDS sample buffer to 95 °C for 5 min. 
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Two hundred nanograms of a galectin was added in one lane as a positive control for the 
subsequent Western blotting and the visualization of distinct proteins with the ECL system. 
The proteins were separated using the Bio-Rad Mini-Protean II system. The gel was cast 
using two different layers of acrylamide concentrations, one on top of the other. First, the 
components of the resolving gel were mixed and poured into the space between two glass 
plates to a height of 5.5 cm. Isopropanol covered the surface of the resolving gel to avoid 
evaporation and contact to the air, and the gel was left for 45 min at room temperature until 
polymerization was complete. Isopropanol was then thoroughly washed away with aqua dest., 
and the stacking gel was poured over the resolving gel to the top of the glass plates. A Teflon 
comb was placed into the stacking gel to create ten slots for the samples while the gel was left 
to polymerize for an additional 30 min. The gel cassette sandwich was then placed into the 
Electrode Assembly, which was then lowered into the Mini Tank. Three hundred fifty 
milliliters electrophoresis buffer were filled into the tank, which surfaced just above the top of 
the gel, and the samples were carefully pipetted into the gel pockets. Electrophoresis was then 
started and kept at a constant current of 200 V for approximately 45 min until the 
bromophenol blue left the gel. The gel was finally removed from the electrophoresis chamber 
and after removing the stacking gel the resolving gel was prepared for transfer of the proteins 
to a nitrocellulose membrane. 
3.4.3 Electrophoretic Transfer of Protein to Nitrocellulose 
Blotting buffer: 
100 ml Tris-glycine 10 x stock solution  
200 ml methanol 
aqua dest. ad 1,000 ml, stored at 4 °C 
0.1 % Ponceau S sodium salt (w/v) (Sigma, P-3504) in 1 % acetic acid (v/v): 
1 ml acetic acid 
100 mg Ponceau S 
aqua dest. ad 100 ml 
Blocking solution: 5 % skim milk powder (w/v) in T-TBS buffer 
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Protein transfer from an SDS gel to a nitrocellulose membrane was performed essentially as 
described by Towbin et al. 109. Electroblotting was carried out using a Bio-Rad Mini-Trans 
Blot Cell system according to the manufacturer’s instructions. Briefly, the gel was 
equilibrated in ice-cold blotting buffer three times for 10 min. A piece of nitrocellulose 
membrane that had been cut according to the size of the resolving gel, two fiber pads and six 
pieces of blot absorbent filter paper (also cut to fit) were soaked in ice-cold blotting buffer for 
30 min. In order to prevent air bubbles getting trapped in the system, a few millimeters of 
blotting buffer was poured between each layer of one fiber pad, three gel-sized pieces of filter 
papers, the nitrocellulose membrane, the gel, three filter papers and the other fiber pad. This 
was placed into the gel holder cassette and then closed. The cassette was placed into the 
electrode assembly, which itself was placed in the buffer tank. After positioning the frozen 
Bio-Ice cooling unit (basically a container with ice) into the buffer tank, it was filled with 
blotting buffer and a magnetic stirring bar was added. Placing the Blot Cell system onto a 
magnetic stirring device set at full speed helped maintain even buffer temperature and ion 
distribution in the tank. The blot was run at constant voltage of 100 V for 90 min. Upon 
completion of the run, the blotting sandwich was disassembled, and the membrane was air 
dried for 5 min. The positions of the lanes of protein and the quality of the blot were 
ascertained by staining the proteins with Ponceau S solution. After marking the size of the 
positive control and the positions of the lanes with a ballpoint pen, the nitrocellulose 
membrane was washed with T-TBS buffer. 
3.4.4 Detection of Galectins on the Blot 
Tris-buffered saline (TBS) 10 x (0.5 M Tris, 1.5 M NaCl), pH 7.5: 
60.50 g Tris-base 
87.66 g NaCl 
aqua dest. ad 1,000 ml, pH 7.5, stored at 4 °C 
Tris-buffered saline 1 x with 0.05 % Tween-20 (v/v) (T-TBS): 
100 ml TBS, 10 x 
500 µl Tween-20 
aqua dest. ad 1,000 ml, prepared just before use 
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Blocking solution:  
5 g skim milk powder, blotting grade 
T-TBS ad 100 ml, prepared just before use 
Primary antibodies: 
polyclonal rabbit-anti-galectin-1 IgG, 1:500 (2 µg/ml) 
polyclonal rabbit-anti-galectin-2 IgG, 1:2,000 (0.5 µg/ml) 
polyclonal rabbit-anti-galectin-7 IgG, 1:1,000 (1 µg/ml) 
All anti-galectin IgG antibodies were supplied by our laboratory. 
Secondary antibody goat-anti-rabbit IgG-peroxidase conjugate (Sigma, A-6154), 1:2,000 
(0.5 µg/ml) 
Primary and secondary antibodies were diluted in blocking solution and a total volume of 
5 ml was used for each of the incubation steps. 
ECL Western Blotting Detection Reagents (Amersham Biosciences) 
12.5 % acetic acid (v/v) in aqua dest. 
Kodak Professional D19 Developer (Sigma, P-5670), 15.6 g/100 ml aqua dest. 
Kodak Fixer solution (Sigma, P-6557), 18.4 g/100 ml aqua dest. 
Immunodetection blotting was performed to detect the presence of distinct proteins with 
specific antibodies in order to determine the galectin content in the cells. To block any 
antigen-independent binding of proteins, the nitrocellulose membrane was exposed to 
blocking solution for 1 hour at room temperature. Incubation of the membrane with 5 ml of 
the antibody solutions was carried out in 50 ml conical centrifuge tubes on a rotator to 
guarantee even distribution of the reagents on the membrane, while minimizing the necessary 
quantities of reagents for the experiment. The nitrocellulose membrane was first incubated 
with the primary antibodies to bind the target galectins overnight at 4 °C. After washing the 
membrane with 30 ml of T-TBS buffer three times quickly, then three times for 10 min, the 
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blots were incubated with solution containing the secondary antibody goat anti-rabbit 
immunoglobulin-peroxidase conjugate for 1 hour at room temperature. The blots were washed 
in the same manner as after the incubation with the primary antibody. Finally, bound 
secondary antibodies were visualized using the ECL Western blotting detection kit 
(Amersham Biosciences) following the manufacturers instructions. The substrate solution was 
prepared briefly before use and pipetted onto the blot, allowing coincubation to proceed for 
1 min. After carefully removing excess liquid with a paper towel, the blot was placed into a 
film cassette and covered with plastic foil. The detection was based on a chemoluminescence 
reaction in which the luminol in the substrate solution is oxidized in the presence of H2O2 by 
the peroxidase conjugated to the secondary antibody. Light was hereby emitted, which was 
detected by exposing the membrane to an x-ray film. The film was then incubated in 
developer solution for approximately 90 sec until bands began to appear. Transferring the film 
to 12.5 % acetic acid (v/v) solution stopped the reaction and the film was then placed in fixer 
solution until the background was clear. Finally, the film was washed thoroughly in aqua dest. 
and air-dried. 
To ascertain the resistance to possible interfering factors in cell extracts, SDS-PAGE and 
subsequent Western blot were carried out with different amounts of recombinant galectin 
(50 - 400 ng) with and without HCT-15 WT cell extract. 
3.4.5 Enzyme Linked Immunosorbent Assay 
Cell lysis buffer for ELISA of cellular extracts, pH 7.2: 
2 mM EDTA disodium dihydrate 0.075 g  
0.25 % Triton X-100 (v/v)   0.25 ml 
2 mM DTT     0.031 g 
2 µg/ml aprotinin   200 µg 
5 µg/ml leupeptin   500 µg 
1 mM pefablock   0.024 g 
20 mM PBS ad 100 ml 
Coating buffer (0.1 M sodium hydrocarbonate, 0.1 M disodium carbonate), pH 9.6: 
2 components:  
0.1 M NaHCO3, 0.84 g ad 100 ml aqua dest. and 
0.1 M Na2CO3, 1.06 g ad 100 ml aqua dest.  
were mixed to reach a pH of 9.6 
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Lyophilized asialofetuin (ASF) and lactose-bovine serum albumin conjugate (Lac-BSA) were 
supplied by our workgroup. 
ASF and Lac-BSA were redissolved in coating buffer to a concentration of 10 µg/ml each. 
ELISA blocking solution: 1 g BSA dissolved in 100 ml 20 mM PBS, pH 7.2 
The primary and secondary antibodies were used in the same concentration as for the 
detection on the nitrocellulose membrane (see 3.4.4). 
Primary and secondary antibodies were diluted in ELISA blocking solution and a total 
volume of 100 µl per well was used for each of the incubation steps. 
After coating and between each incubation step, the wells were washed four times with 200 µl 
of 20 mM PBS, pH 7.2. 
Cell lysates and positive controls were diluted in ELISA blocking solution to a volume of 
100 µl per well. 
OPD buffer (50 mM disodium hydrophosphate, 20 mM citric acid), pH 5.0: 
1.78 g Na2HPO4 x 2 H2O  
0.84 g citric acid monohydrate 
aqua dest. ad 200 ml 
OPD solution: 
 10 mg o-phenylenediamine dihydrochloride (OPD) 
 10 µl 30 % H2O2 
 OPD buffer ad 10 ml, prepared just before use 
Stopping solution: 0.1 M H2SO4 
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An ELISA was developed to gain additional information of the actual active lectin activity of 
galectins-1, -2 or -7 in the transfected and control cells. A known ligand for the galectins 
served as a matrix to assess binding activity. This was either asialofetuin (ASF) or lactose-
bovine serum albumin-conjugate (Lac-BSA), a chemically prepared glycoprotein 110. 
Preparation of cells was identical as for SDS-PAGE analysis (see 3.4.1) except the lysis 
buffer had to be modified reducing Triton X-100 and excluding sodium deoxycholate and 
lactose, which could otherwise disturb the lectin binding to the matrix. 
Adsorption of the (neo)glycoprotein to the ELISA microplate surface was performed after 
diluting ASF or Lac-BSA in coating buffer to a concentration of 10 µg per ml, then pipetting 
100 µl (1 µg matrix protein) of this solution into each well and finally placing the microplate 
(without a lid or other covering) in an incubator at 37 °C for 12 hours - during which the 
liquid completely evaporated. After this step and between each of the incubation steps, the 
wells of the ELISA microplate were washed four times with 200 µl per well. To inhibit any 
residual binding of proteins to the microplate well surface, the wells were incubated with 
200 µl 1 % BSA in PBS (ELISA blocking solution) at 37 °C. During this and the following 
incubation steps at 37 °C the microplate was covered to minimize evaporation. After the 
blocking procedure saturating the well surface, the cell lysates were added to the wells. Cell 
extract protein was diluted in ELISA blocking solution and 100 µl containing 1,000 µg to 
62.5 µg of cell extract protein (depending on the response in the assay) per 100 µl was added 
to the first well. A concentration row was established diluting each next sample 1:2 with 
ELISA blocking solution and 100 µl of these solutions was added to the ELISA microplate. 
As a positive control and to set a relationship between known galectin content and respective 
response, a concentration row of samples with recombinant galectins-1, -2 or -7 diluted with 
ELISA blocking solution to a concentration between 800 ng and 50 ng (again depending on 
the intensity of the response) per 100 µl in the first sample was made. This was continuously 
further diluted 1:2 with ELISA blocking solution and 100 µl of these samples were added to 
the ELISA microplate. To evaluate the response without galectin (negative control to 
determine background values), 100 µl of ELISA blocking solution was pipetted into each of 
four wells. 
The solutions in the microplate were incubated for 3 hours at 37 °C. To detect the respective 
bound galectin, the ELISA microplate was incubated with the non-cross-reactive primary 
antibody rabbit polyclonal IgG fractions specific for galectin-1, galectin-2 or galectin-7 for 
2 hours at 37 °C. The secondary antibody goat anti-rabbit-IgG-peroxidase conjugate was then 
added to the wells and incubated at 37 °C for 1 hour. Afterwards, 100 µl OPD solution was 
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added to each of the wells and the microplate was incubated at 37 °C for 15 min, during 
which the OPD was processed, dependent on the amount of bound peroxidase, to a more or 
less intensive yellow color. This reaction was stopped by adding 100 µl of 0.1 M H2SO4 to 
each of the wells. The optical density at a wavelength of 490 nm was measured in an ELISA 
minireader. The OD was interpreted as nanogram of bound galectin per µg of cell extract by 
comparing the optical densities with those of the positive control while considering the blank.  
To ascertain the validity of the assay and its lack of impairment by any interfering compounds 
in cell extracts, the reactivity of recombinant galectin was measured with and without tissue 
extracts from bovine heart muscle. Approximately 1 g of frozen adult bovine heart muscle 
tissue was homogenized in 4 ml ice-cold 20 mM PBS, pH 7.2 with an Ultra-Turrax 
homogenizer set to full speed in impulses of ten times 5 sec during which the tissue sample 
was cooled with ice. The homogenate was transferred to 1.5 ml mini test tubes and 
centrifuged at 23,000 x g (13,000 rpm) at 4 °C for 5 min. The supernatant was pipetted into 
new mini test tubes, and the protein concentration was measured as described above. An 
ELISA was performed with 1 µg of ASF coated to each of the wells. Fifteen ng of 
recombinant galectin in 20 mM PBS, pH 7.2 was added to each of the wells with or without 
different quantities (100 µg to 1,000 µg protein) of bovine tissue extract. The response of the 
applied amounts of bovine tissue extract without recombinant galectin was also measured. 
3.4.6 FACS Analysis 
Dulbeco’s phosphate-buffered saline (DPBS) Mg2+ and Ca2+ free, 10 x (27 mM KCl, 14.7 mM 
KH2PO4, 1.38 M NaCl, 80.9 mM Na2HPO4 x 2 H2O), pH 7.2: 
2.0 g KCl 
2.0 g KH2PO4 
80.6 g NaCl 
14.4 g Na2HPO4 x 2 H2O 
ad 1,000 ml aqua dest., stored at room temperature 
DPBS 1 x, pH 7.2: 
100 ml DPBS 10 x 
ad 1,000 ml aqua dest., stored at 4 °C 
Washing buffer: 0.1 % BSA (w/v) in DPBS  
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Primary antibodies: polyclonal rabbit-anti-galectins-1, -2, or -7 IgG diluted to 1 µg/100 µl 
Secondary antibody: anti-rabbit-IgG-FITC conjugate (Sigma, F-0382) diluted to 1 µg/100 µl 
Antibodies were diluted in 0.1 % BSA (w/v) washing buffer 
Centrifugation was always at 800 x g (3,000 rpm, eppendorf centrifuge) for 3 min. 
Flow cytometry allows the counting and analysis of physical and molecular attributes of cells 
in a liquid medium. With the fluorescence activated cell-sorting analysis (FACS-analysis) one 
can quantify the presence of surface receptors as well as intracellular proteins. The analysis is 
based on the specific interaction of antigens with antibodies, which are conjugated to 
fluorescent dyes. During the analysis the suspended cells are hydrodynamically focused and 
pass a laser beam of appropriate wavelength, leading to fluorescence activation and emission. 
The intensity of fluorescent signals is correlated to antigen presence. Additional information 
is given through the scatter signals of the laser itself, such as the cell size. The most often 
used application in flow cytometry, also the aim of these studies, is the analysis of expression 
levels of surface or intracellular determinants based on specific staining of these antigens with 
labeled antibodies on a single-cell level.  
Cells were detached with 20 mM PBS, pH 7.2 containing 2 mM EDTA, counted and 
4 x 105 cells were pipetted into mico-test tubes. No trypsin was added to the detaching 
solution, as this would have changed protein structures on the cell surfaces. After 
centrifugation, the supernatant was removed and the cells were washed with 500 µl ice-cold 
DPBS.  
Extracellular staining 
First, the cells were incubated with 50 µl of the primary antibody diluted in washing buffer 
for 30 min on ice. Then 500 µl washing buffer was added, the cells were centrifuged and after 
discarding the supernatant the cells were washed again in 500 µl washing buffer. The cells 
were incubated with 50 µl of the FITC-labeled antibody diluted in washing buffer for 30 min 
on ice in the dark. As before, the cells were carefully washed twice with washing buffer. 
Pellets were finally resuspended in 300 µl 1 % paraformaldehyde (w/v) and stored at 4 °C for 
at least 1 hour for fixation. 
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As negative controls, two samples of the cell clone were treated in parallel under identical 
conditions as described above, except that the primary antibody or both the primary and the 
secondary antibodies were excluded from the diluting solutions.  
FACS analysis was finally performed using a FACScan flow cytometer with CellQuest 
software (Becton Dickinson). 
3.4.7 Cytochemical Analysis 
Poly-L-lysine solution: 0.2 mg/ml in sterile PBS (20 mM, pH 7.2) 
2 % paraformaldehyde (w/v) in 20 mM PBS, pH 7.2 
Sterile coverslips were incubated with 100 µl of the poly-L-lysine solution for 30 min at 
37 °C. They were washed with sterile PBS and left to dry. HCT-15 cells were detached with 
20 mM PBS, pH 7.2 containing 2 mM EDTA. No trypsin was added to the detaching solution, 
as this would have changed protein structures on the cell surfaces. Ten thousand cells in 
100 µl medium were plated onto the poly-L-lysine coated area of the coverslip and incubated 
for 2 hours at 37 °C. The coverslips were carefully washed with 20 mM PBS, pH 7.2 and fixed 
in 2 % paraformaldehyde (w/v) for 5 min at room temperature. They were then washed three 
times for 5 min in PBS. Immunocytochemical and cytomorphological processing of the cells 
was performed in the lab of Prof. Dr. Smetana (Charles University, Prague) as previously 
described 111. 
3.5 Molecular Biology 
3.5.1 Isolation of Genomic DNA 
Wizard Genomic DNA purification kit (Promega, Mannheim, Germany) 
DNA rehydration solution (Promega) 10 mM Tris-HCl, 1 mM EDTA, pH 7.4 
Isolation of genomic DNA was done using the Promega Wizard Genomic DNA purification 
Kit according to the manufacturer’s instructions. Two million cells were trypsinized, 
harvested and transferred to a 1.5 ml mico-test tube. They were centrifuged at 10,000 x g for 
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10 sec to pellet the cells. The supernatant was removed and after a washing step with 20 mM 
PBS, pH 7.2, 600 µl nuclear lysis solution was added. This was carefully pipetted up and 
down until the solution was homogeneous. Three microliters of RNase solution was added to 
the nuclear lysate and manually inverting the tube a few times mixed the sample. After 
incubation for 30 min at 37 °C the sample was cooled to room temperature. Subsequently, 
200 µl of protein precipitation solution was added, vortexed vigorously and chilled on ice for 
5 min. After centrifugation for 4 min at 13,000 x g the supernatant containing the DNA was 
transferred to a micro-test tube with 600 µl of room-temperatured isopropanol and was gently 
mixed by inversion until the white thread-like strands of DNA formed a visible mass. 
Following a centrifugation step (1 min at 13,000 x g) the DNA pellet was washed with 600 µl 
70 % ethanol (v/v) at room temperature. After centrifugation (1 min at 13,000 x g) the 
supernatant was carefully discarded, the DNA pellet air dried for 15 min and dissolved in 
100 µl DNA rehydration solution at 65 °C for 1 hour. The DNA concentration of the solution 
was then measured photometrically at a wavelength of 260 nm (E = 1 at 50 µg/ml DNA), and 
0.5 µg genomic DNA was used in the PCR assay described below. 
3.5.2 RNA Extraction, Reverse Transcription of RNA and PCR 
Analysis 
RNeasy Mini Kit (Qiagen, Hilden, Germany) 
First strand buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 15 mM MgCl2) 
Total RNA from 2 x 106 cells was isolated using an RNeasy Mini Kit (Qiagen) according to 
the manufacturer’s directions. The integrity of the RNA was verified by separating an aliquot 
of 1 µg of total RNA by agarose gel electrophoresis. Intact RNA was separated into compact 
bands of distinct sizes. The following procedures were performed as previously described 102. 
Briefly, an aliquot of 1 µg of total RNA was used as a template for first strand synthesis of 
cDNA. Reverse transcription was performed for 50 min at 42 °C in a 20 µl reaction volume 
containing first strand buffer, dNTPs (1 mM each), oligo(dT)12-18 primer (0.5 µg), 200 units 
Superscript II RNase H- Reverse Transcriptase and DEPC-treated water. The reaction was 
terminated by incubation at 70 °C for 15 min. An aliquot of 2 µl of the probe were then used 
in the following PCR amplification. The primer pairs used for RT-PCR amplification of 
cDNAs specific for galectins-1, -2, -7 and actin are shown in table 7. 
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Table 7. Primer pairs used for RT-PCR amplification of galectins-1, -2, -7 and actin. 
Primer Sequence Locationa Sizeb 
Galectin-1#1 5’-AAC CTG GAG AGT GCC TTC GA-3’ 45 - 64 323 
Galectin-1#2 5’-GTA GTT GAT GGC CTC CAG GT-3’ 367 - 348  
Galectin-2#1 5’-ATG ACG GGG GAA CTT GAG GTT-3’ 27 - 47 358 
Galectin-2#2 5’-TTA CGC TCA GGT AGC TCA GGT-3’ 384 - 364  
Galectin-7#1 5’-ATG TCC AAC GTC CCC CAC AAG-3’ 19 - 39 282 
Galectin-7#2 5’-TGA CGC GAT GAT GAG CAC CTC-3’ 300 - 280  
β-Actin#1 5’-GGC ATC GTG ATG GAC TCC G-3’ 521 - 539 612 
β-Actin#2 5’-GCT GGA AGG TGG ACA GCG A-3’ 1133 - 1115   
a Numbers designate the base pair positions according to published cDNA sequences 
b Predicted size of the correct fragment 
PCR was performed after an initial denaturation step at 95 °C for 5 min for 30 cycles 
(denaturation at 95 °C for 35 sec, annealing at 58 °C for 55 sec, extension at 72 °C for 
40 sec). The final extension step was performed at 72 °C for 5 min. 
3.5.3 Agarose Gel Electrophoresis 
EDTA solution, 0.5 M, pH 8.0: 
186.12 g EDTA disodium dihydrate  
ad 1,000 ml aqua dest. 
TAE buffer, 50 x (2 M Tris-Acetate, 50 mM EDTA) buffer: 
242 g Tris-base  
57.1 ml glacial acetic acid (acetic acid ≥ 99.7 %) 
0.5 M EDTA (pH 8) 100 ml 
ad 1,000 ml aqua dest., autoclaved and stored at room temperature 
TAE buffer, 1 x (0.04 M Tris-Acetate, 1 mM EDTA): 
20 ml TAE buffer, 50 x 
ad 1,000 ml aqua dest., stored at room temperature 
SeaKem LE Agarose (BioWhittaker Molecular Applications) 
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Ethidium bromide stock solution: 10 mg/ml (Sigma), stored at 4 °C and protected from light 
Loading Dye solution, 6 x (Fermentas) 
GeneRuler 100 bp DNA Ladder plus (Fermentas) 
Amplified Products were separated by means of electrophoresis in 2 % agarose (w/v) gels. 
Specifically, SeaKem agarose was heated in the microwave in TAE buffer (1 x) until the 
agarose was completely dissolved and the solution was then left to cool to approx. 60 °C. To 
visualize the DNA bands, 5 µl of the DNA intercalating agent ethidium bromide per 100 ml 
agarose solution was added and mixed evenly in the solution by swirling the container. The 
solution was then poured into a gel chamber into which a comb had been inserted to generate 
pockets in the gel for the samples, and allowed to cool down and harden. The gel was then 
transferred to a gel chamber, which was filled with 1 x TAE buffer. DNA or standard size 
marker was dissolved in 6 x loading dye solution and was transferred into the slots of the gel. 
The DNA products were subjected to electrophoresis at a constant voltage until the samples 
had sufficiently been separated in the gel, which was visible by the dye in the loading buffer. 
The DNA was finally visualized by ultraviolet light and photographed. 
3.6 Video Microscopy 
Monitoring of cell populations by video microscopy and recording of snapshots after constant 
intervals was performed by a SAMBA 2005 computer-assisted microscope system (Samba 
Technologies, Grenoble, France) with a x 20 (aperture 0.50) magnification lens. Video 
microscopic analysis of the cells was performed in the lab of Prof. Dr. R. Kiss (Université 
Libre de Bruxelles, Brussels) as previously described 112. 
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3.7 Assays with Cell Lines 
3.7.1 Methylcellulose Assay 
DMEF/F-12 doubly-concentrated: 
15.57 g DMEM/F-12 (1:1) powder (Gibco BRL)  
ad 500 ml (instead of 1,000 ml for cell culture medium) autoclaved Millipore water 
sterile filtered 
Methylcellulose solution: 
8.8 g methylcellulose (Fluka Chemie) 
188 ml DMEM/F-12 double-concentrated medium 
1.125 g NaHCO3 
ad 500 ml autoclaved Millipore water 
Methylcellulose solution was autoclaved with a stir bar in a 1,000 ml bottle. Two hundred 
eight milliliters of autoclaved Millipore water were then added. The solution was boiled and 
left to cool to room temperature in three cycles while being stirred. One hundred eighty-eight 
milliliters of double-concentrated DMEM/F-12 and 1.125 g NaHCO3 were added after which 
the pH value was adjusted to 7.2. The volume was then set to 500 ml with autoclaved 
Millipore water, the solution was filtered to establish sterility and stirred for 48 hours at 4 °C, 
before it was finally aliquoted and stored at -20 °C. 
Suspension of cells in methylcellulose: 
4.7 ml methylcellulose solution 
4.3 ml cell suspension with a total of 104 cells in RPMI-1640 medium 
1 ml FCS 
In this assay setting, cells were grown in tissue culture medium containing highly viscous 
methylcellulose. This kept the cells from adhering directly to the cell culture flask. The ability 
of cells to proliferate in the absence of adhesion, termed anchorage-independent growth, is a 
main characteristic of transformed cells and is an important feature of tumorigenicity 113.  
A cell suspension was prepared in RPMI medium, FCS and methylcellulose. After vortexing 
at maximum speed for 10 sec an aliquot of 2 ml was pipetted into each of three 35 mm Petri 
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dishes. These were then incubated at 37 °C for 10 days. Decisive criterion was the ability of 
the non-adherent cells to grow into cell clones that were identified as single colonies. These 
were counted by monitoring cells through an invertoscope while placing the Petri dishes onto 
a gridded glass plate. 
3.7.2 Doubling Time 
Cells were detached, and a cell suspension was made containing 5 x 104 cells per ml in culture 
medium. A total of 12 wells per cell clone (three per day, 4 days) of a 24-well plate already 
containing 1 ml of cell growth medium were filled with a 1 ml aliquot of the cell suspension. 
The cells were incubated for 72 hours (until day 3) during which the cells were allowed to 
“recover” from the previous handling, leave the quiescent phase and enter exponential 
growth. Then cells were detached with 300 µl Trypsin-EDTA solution per well. Depending 
on cell density a 100 µl to 200 µl aliquot of the cell suspension was transferred to a micro-test 
tube and diluted with PBS-EDTA as necessary. The cell number was determined, while 
taking the total volume of the cell suspension, the aliquot taken and the dilution factor into 
consideration. The mean cell number of three wells represented the cell count for that day. 
This procedure was repeated on days 4, 5 and 6. 
Assessment of the doubling time was performed by first setting the cell numbers into relation 
to the hours that had passed after seeding. To ascertain that the cells were in the exponential 
phase of growth, that they had left the quiescent phase and that cell growth was later not 
attenuated, i.e. by density-dependent inhibition, a graph was plotted setting the hours into 
relation to the logarithm of the according cell numbers. Exponential cell growth should reach 
a linear relationship at this point. If a cell count at the beginning or end of the assay did not 
meet these terms, it was not included in the equation of the doubling time. 
An exponential function f(x) = b * mx that best fit the obtained data was computed by 
regression analysis using the computer program Microsoft Excel.  
f(x)  cell numbers 
x  hours after seeding 
b  a constant defining the cell number at x = 0  
m  the base of the exponential function 
b and m were computed by the program Excel 
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The calculation was transformed expressing the doubling time (dt) through m: 
if x = dt then 
f(dt) = b * mdt = 2 * b  /b 
mdt = 2    ln (natural logarithm) 
ln(mdt) = ln(2) 
dt * ln(m) = ln(2)  /ln(m) 
dt = ln(2)/ln(m) 
doubling time = ln(2)/ln(m)  
3.7.3 MTT Assay 
96-well F-Plate 
RPMI-1640 medium with 1 %, 2 %, 3 % or 10 % FCS (v/v) 
MTT stock solution (0.5 % MTT (w/v)) 10 x: 
 50 mg MTT dissolved in 10 ml 20 mM PBS, pH 7.2, sterile filtered and stored at 4 °C 
MTT medium: 
 MTT stock solution was diluted 1:10 in RPMI-1640 medium, prepared just before use 
Chemotherapeutical agents: 
Irinotecan hydrochloride trihydrate (CPT-11) and SN38 (7-ethyl-10-hydroxycamptothecin) 
were kindly supplied by Prof. Dr. R. Kiss (Brussels, Belgium). 
Oxaliplatin stock solution: 5 mg of oxaliplatin (Sigma, Product No. O-9512) were dissolved 
in 2 ml of 20 mM PBS, pH 7.2. 
Irinotecan stock solution: 1.5 mg irinotecan were dissolved in 20 µl of a solvent consisting of 
80 % ethanol (v/v) and 20 % DMSO (v/v) (EtOH:DMSO 80:20). 
SN38 stock solution: 1 mg SN38 was dissolved in 637.4 µl EtOH:DMSO 80:20. 
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The stock solutions of the chemotherapeutical agents were diluted in cell growth medium 
shortly before addition to the cells to the following concentrations: 
oxaliplatin: 10-4 M, 10-5 M, 10-6 M, 10-7 M 
irinotecan: 10-4 M, 10-5 M, 10-6 M, 10-7 M 
SN38: 10-6 M, 10-7 M, 10-8 M, 10-9 M 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay, first described by 
Mosmann 114, is based on the ability of a mitochondrial dehydrogenase from viable cells to 
cleave the tetrazolium rings of the pale yellow MTT and form dark blue formazan crystals 
which are largely impermeable to cell membranes, thus resulting in their accumulation in 
viable cells. Solubilization of the cells by the addition of a detergent results in the liberation 
of the crystals, which are dissolved. The number of viable cells is directly proportional to the 
level of the formazan product created. The intensity of the developed colored product can 
then easily be quantified with an ELISA reader.  
Because sterile conditions could not be kept during the final evaluation of the assay, i.e. when 
placing the microplate in the ELISA reader, one microplate was used for each day that the 
MTT cleavage was to be measured. After detaching and counting the cells, a cell suspension 
was made with 2 x 104 cells per ml of medium made up of RPMI-1640 medium, 
supplemented with the usual amount of penicillin, streptomycin, L-glutamine (see 3.3.2) and 
10 % of FCS (v/v). To assess cell viability under stress conditions with reduced FCS content, 
cells were resuspended in medium with 1 %, 2 %, 3 % FCS (v/v). 
Five wells were each filled with 100 µl of cell suspension (2,000 cells) for every cell line and 
day that was to be assessed. The wells on each side were not used for the assay but were filled 
with 20 mM PBS, pH 7.2 instead, as these were more subject to evaporation than the other 
wells. The microplates were then placed in the incubator. Unless declared otherwise, the 
medium was not exchanged until the date of evaluation. This prevented the unwanted 
detachment of cells, which might occur during the removal or addition of medium. 
When examining susceptibility to stress by the cytotoxic agents oxaliplatin, irinotecan and 
SN38, the cells were first plated in medium without the chemotherapeutical agents. After 
24 hours, the medium was exchanged with medium containing the cytostatics in four 
concentrations (oxaliplatin and irinotecan: 10-4 to 10-7 M; SN38: 10-6 to 10-9 M). Each 
concentration was diluted to the next lower concentration 1:10. For comparison, cells were 
plated in parallel with medium or in cases where a solvent had to be used, with medium and 
the applied amounts of solvent. The cells were then incubated for 72 hours. 
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The protocol started by exchanging the medium with 100 µl of the MTT medium per well. 
The cells were then placed back into the incubator for 2 (assessment of cell growth in 
different FCS concentrations) or 4 hours (measurement of susceptibility to cytotoxic agents). 
The MTT solution was subsequently removed and 100 µl of DMSO was pipetted to each 
well. The cells were lysed, and the dark blue formazan reaction product was evenly 
distributed in the solution by repeatedly pipetting DMSO up and down and also by stirring the 
pipette in the well. One hundred microliters of DMSO in previously empty wells served as the 
negative value. The microplate was finally placed in an ELISA reader and the optical density 
of the wells was measured at a wavelength of 595 nm. 
3.7.3.1 Determination of the IC50 Value of Cytotoxic Agents 
The percentage of the optical density compared to that of the control was displayed in a 
diagram in relation to the concentrations of the cytotoxic agent on a logarithmic scale. The 
effect of the agent was described as the concentration responsible for 50 % inhibition of the 
control value (IC50). This was evaluated by first describing a linear function f(x) = k * x + d 
with the values closest to the 50 % mark (x1, y1 and x2, y2).  
f(x)  percent of the measured optical density in relation to the control value 
x  log(concentration of the cytotoxic agent) 
k  constant defining the inclination of the linear curve 
d constant defining f(x) at  x = 0  
x1 logarithmic value of the applied concentration of the cytotoxic agent responsible for a 
response just below 50 % 
y1 response of x1 
x2 logarithmic value of the applied concentration of the cytotoxic agent responsible for a 
response just above 50 % 
y2 response of x2 
k = (y2 - y2)/(x1 - x2) 
d = y1 - k * x1 
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Evaluation of IC50: 
C = log(IC50) 
50 = k * C + d 
C = (50 - d)/k 
IC50 = 10C 
3.7.4 Statistical Analyses 
The paired two-tailed Stundent’s t-test was used to analyze the differences between data 
determined for the analyzed cells and the mock-transfected cells treated under identical 
conditions. Determined p-values ≤ 0.05 were defined as significant. 
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4 Results and Discussion 
4.1  Characterization of Cell Clones 
4.1.1 Generation and Selection of Stable Cell Clones 
Neomycin-kanamycin aminoglycoside antibiotics such as G418 block protein synthesis in 
mammalian cells by interfering with ribosomal function 115. HCT-15 and DLD-1 cells were 
transfected with a galectin-cDNA-carrying vector. The vector also contained an 
aminoglycoside phosphotransferase gene, resulting in detoxification of neomycin-kanamycin 
antibiotics 115. This conferred resistance of the cells to otherwise lethal concentrations of 
antibiotic in the medium. Therefore, the presence of G418 in the medium enabled selection of 
vector-positive cells from the population. Having acquired stable transfectants by this 
selection procedure, the next step was to analyze the genomic DNA of each cell clone. 
4.1.2 DNA and RNA Analysis 
G418 resistance over a period of 2 weeks makes it likely that plasmid DNA of the remaining 
viable cells is stably associated with high molecular weight cellular DNA115. This was 
verified by examining the genomic DNA of the HCT-15 cells for the encoded galectins. After 
the genomic DNA of the cells was extracted, the presence of the galectin-specific DNA was 
confirmed by using suitable primers. If successful, DNA of predicted size would be amplified 
by the polymerase chain reaction. To detect transcription of galectin-specific DNA to RNA, 
the RNA of the cells was extracted and rewritten as cDNA by reverse transcription. The 
cDNA encoding the galectins was then similarly searched for by PCR. The DNA mixture was 
finally separated by agarose gel electrophoresis and the bands were visualized by ethidium 
bromide in ultraviolet light.  
Figures 5 and 6 show agarose gels with the amplified products generated by this assay. The 
size of the resulting products was determined by comparison to a 100 bp DNA ladder added 
as calibration of length next to the samples.  
RNA can easily be degraded by RNase activity. This would lead to false negative results 
when analyzing transcription levels. The integrity of the RNA was therefore confirmed by 
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cDNA 
genom. 
DNA  
evaluating an aliquot of 1 µg of total RNA by agarose gel electrophoresis. Intact RNA would 
be separated into compact bands of distinct sizes. This is shown in figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: PCR and RT-PCR analysis. Amplified products from cDNA (a - e, g - k) or from genomic 
DNA (n - r, t - x). Searching for galectin-1 (323 bp) a - f and n - s; galectin-2 (358 bp) g - l and 
t - y. Negative controls without template: f, l, s, and y. Extracts from WT (a, g, n, t) and mock-
transfected cells (b, h, o, u). Cells transfected with galectin-1-specific cDNA: clone 17w (c, p), 35m 
(d, q) and 72s (e, r). Cells transfected with galectin-2-specific cDNA: clone 27w (i, v), 21m (j, w) 
and 18s (k, x). The size was determined by comparison to a 100 bp DNA ladder added next to the 
samples. 
The results substantiated the successful vector transfection of the selected cell clones, leading 
to incorporation of the respective sequences into the genomic DNA. The vector DNA was 
distinguishable from naturally present genomic DNA, encoding the respective galectins 
independent of vector transfection. Primer pairs were selected that would include intron 
sequences incorporated in naturally present genomic DNA. Only sequences amplified from 
vector DNA yielded PCR products of the expected size. 
Amplification of cDNA confirmed presence of galectin-1-, galectin-2- or galectin-7-specific 
mRNA in clones transfected with the respective galectin-cDNA. A sign of the presence of 
galectin-1-specific cDNA was seen in wild-type (WT) and mock-transfected cells. No signal 
indicative of galectin-2- or galectin-7- specific mRNA was found encoded in WT or mock 
cDNA. As internal loading control, β-actin DNA was amplified in the same manner. To 
gal-1 gal-2 
  a    b    c     d    e    f                 g    h     i     j     k     l 
 n    o    p    q    r     s                 t     u    v    w    x    y 
500 bp 
500 bp 
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exclude erroneous signal appearance in the absence of total cDNA, a parallel sample was run 
without a template but was otherwise treated identically. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: PCR and RT-PCR analysis. Amplified products from cDNA (A - E, G - M) or from 
genomic DNA (N - R, T - Z). Searching for galectin-7 (282 bp) A - F and N - S; or for β-actin 
(612 bp) G - M and T - Z. Negative controls without template: F and S. Extracts from WT (A, N) and 
mock-transfected cells (B, O). Cells transfected with galectin-7-specific cDNA: clone 19w (C, P), 
13m (D, Q) and 2s (E, R). The size was determined by comparison to a 100 bp DNA ladder added 
next to the samples. 
 
 
 
 
 
 
 
Figure 7: Illustration of the integrity of RNA. In agarose gel electrophoresis, intact RNA separated 
into compact bands of distinct sizes. One microgram of total RNA extract of HCT-15 WT, mock-
transfected and the galectin-1- (clone 17w, 35m, 72s),  -2- (clone 27w, 21m, 18s) and -7- 
(clone 19w, 13m, 2s) cDNA-transfected-cells was inspected for signs of RNA degradation. RNA 
extracts from clones 2s (a); 13w (b); 17w (c); 18s (d); 19m (e); 21m (f); 27w (g); 35m (h); 72s (i); 
and from WT (j); and mock-transfected cells (k). 
 A      B      C      D       E      F                 G      H       I         J      K       L      M 
 N      O      P      Q      R      S                  T      U      V      W      X       Y       Z 
500 bp 
500 bp 
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After analyzing the HCT-15 cells on the level of DNA/RNA, the next question was addressed. 
This dealt with the consequences of the verified galectin-specific DNA/RNA content in the 
cells. The resulting quantity of the respective galectin protein was evaluated in each of the cell 
clones. 
4.1.3 Analysis of Galectin Protein by ECL Blot 
The aim of analyzing the galectin protein content of the HCT-15 cells was to find cell clones 
overexpressing the respective galectin. This would enable the confirmation of a galectin-
specific effect with more than one cell clone. Additionally, by using clones with a low, 
medium and high content of galectin, information on whether and how an effect might be 
quantity-dependent could also be collected. 
As a first step in assessing the quantity of galectins-1, -2, or -7 proteins, the cells were lysed 
and the extracts were analyzed by means of SDS-PAGE and subsequent Western blotting, 
after which the presence of galectin was monitored by the ECL system. 
To ensure that components of the cell extract did not influence the reactivity of the galectin in 
this assay, resulting in false-negative results, a control was run in parallel. This control 
consisted of recombinant galectin-2 concentrations in the range from 400 ng down to 50 ng - 
without or with addition of 50 µg protein of HCT-15 WT cell extract. As shown in figure 8, 
no differences that could be attributed to the presence of cell extract could be seen. This result 
confirms the experimental conditions of the cell lysates preparation, SDS-PAGE and ECL 
blot to be appropriate. 
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Figure 8. Influence of cell extract on ECL reactivity. Recombinant 
galectin-2 without (-) or with (+) 50 µg protein of HCT-15 WT cell 
extract. a: 400 ng; b: 200 ng; c: 100 ng; or d: 50 ng of galectin-2. Film 
was exposed for 1 min. 
When systematically screening the selected cultures, transfectants were found with very 
different levels of galectin content in the cell lysates. Protein levels ranged from a barely 
visible response in the ECL system to high quantities, relative to the positive control of 0.2 µg 
galectin. Also, some clones were found that did not contain the respective galectin. 
During evaluation of HCT-15 cells on their galectin-1 content, blots sporadically showed a 
slight reactivity in WT and mock cells, indicating a low baseline production of galectin-1 in 
these cells. Galectin-2 or galectin-7 were never in seen the HCT-15 WT or mock cell lysates. 
After testing each clone in at least five independent blotting experiments, three cell clones of 
the galectin-1-cDNA-transfected cells, three cell clones of the galectin-2-cDNA-transfected 
cells and three cell clones of the galectin-7-cDNA-transfected cells were chosen. Their 
response in the ECL system were weak, medium or strong compared to the positive control of 
the respective galectin. The name of the clone was extended by the clone number with "w" for 
weak, "m" for medium or "s" for strong to define these clones. Figures 9 - 11 illustrate the 
different intensity levels for each series of transfectants after ECL processing. 
  a-  a+  b-  b+  c-  c+  d-  d+ 
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Figure 9. Galectin-1 in HCT-15 Cells. ECL 
blot using anti-gal-1 IgG as primary reagent. 
a: 0.2 µg recombinant human galectin-1 as 
positive control; b - f: 50 µg cell extract 
protein from b: WT, c: mock-transfected, and 
galectin-1-cDNA-transfected cells: d: clone 
17w, e: clone 35m, f: clone 72s. Film was 
exposed for 1 min. 
 
 
 
 
Figure 10. Galectin-2 in HCT-15 Cells. ECL 
blot using anti-gal-2 IgG as primary reagent. 
a: 0.2 µg recombinant human galectin-2 as 
positive control; b - f: 50 µg cell extract 
protein from b: WT, c: mock-transfected, and 
galectin-2-cDNA-transfected cells: d: clone 
27w, e: clone 21m, f: clone 18s. Film was 
exposed for 5 min. 
 
 
 
Figure 11. Galectin-7 in HCT-15 Cells. ECL 
blot using anti-gal-7 IgG as primary reagent. 
a: 0.2 µg recombinant human galectin-7 as 
positive control; b - f: 50 µg cell extract 
protein from b: WT, c: mock-transfected, and 
galectin-7-cDNA-transfected cells: d: clone 
19w, e: clone 13m, f: clone 2s. Film was 
exposed for 1 min. 
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After a first quantification of the galectin protein in the cells by the ECL blot processing, 
further characterization of the overexpressed galectin was necessary. The most well known 
feature of galectins is their ability to bind β-galactosides. The binding capacity of the 
overexpressed galectins to known ligands was investigated in the next procedure. 
4.1.4 Enzyme Linked Immunosorbent Assay 
The conditions of an ELISA were adapted to quantify the binding of galectins to a matrix 
presenting suitable ligands of these lectins. HCT-15 cell extracts of WT, mock-transfected 
cells and cells transfected with cDNA specific for galectins-1, -2, and -7 were subjected to 
this assay. ELISA plates were prepared with a matrix (asialofetuin or lactose-conjugated 
BSA), known to present suitable ligands for galectins116. Cell extracts were incubated in these 
plates, and the binding of the galectins was assessed by staining them with 
peroxidase-conjugated antibodies specific for the respective galectins. This ultimately led to 
an enzymatic reaction causing an increase of concentration of photometrically active 
substance. The optical density was then measured in a minireader. 
When measuring the response of the galectin-1-cDNA-transfected cells, intensities of the 
reaction were very different between independent experiments. Results of galectin-2 and 
galectin-7 activity in this assay was contradictory, as the response was often inversely 
proportional to the added amount of cell extract protein. The determined quantity of bound 
recombinant galectin to the matrix was conclusive, though. It was assumed that substances in 
the lysis buffer interfered with binding of galectin to the matrix. However, experiments with 
recombinant galectin and different compositions of the lysis buffer could not unambiguously 
solve the problem. Next, the influence of the cell extract itself was examined. The response of 
recombinant galectin was measured in the presence or absence of HCT-15 cell extracts, which 
had been homogenized in 20 mM PBS, pH 7.2 instead of lysis buffer. The results showed a 
marked reduction of the signal by the cell extracts. To determine whether this was a unique 
characteristic of extracts of HCT-15 cells, the assay was repeated with adult bovine heart 
muscle extracts, which had also been homogenized in 20 mM PBS, pH 7.2. While the extract 
itself was not reactive, it effectively reduced the response in assays with recombinant galectin. 
The evaluation of the carbohydrate-binding activity of the overexpressed galectins was not 
possible because of the inherent inhibiting properties of cellular extracts in this assay, leading 
to inherently ambiguous data. Therefore, further characterization of the HCT-15 galectin-
overexpressing cells was pursued. 
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It has been demonstrated that members of the galectin family such as galectin-1 are not 
confined to the intracellular space, despite the absence of a typical secretion signal peptide 117. 
Hughes describes the secretion and cell surface presentation of galectins as a common 
event 118. In a study presented by Kopitz et al., the interaction of galectin-1 with the 
ganglioside GM1, which are both present on the surface of neuroblastoma cells, is described. 
The data are indicative that the trans binding action of these two binding partners on 
neighboring cells is responsible for cell density dependent differentiation and growth arrest 76. 
In order to assay comparable functions in the present study, information had to be gained on 
the HCT-15 cell surface presentation of the overexpressed galectins. To address this question, 
cells were processed by FACScan analysis. 
4.1.5 FACS Analysis 
FACS analysis quantifies the amount of bound FITC-conjugated antibody in each cell of a 
population. This enabled a conclusion to be made on the distribution of fluorescence intensity 
among the cells analyzed. If nearly all cells had a certain amount of bound antibody, then a 
sharp peak was the result in the readout. A more even distribution resulted in a wider peak. 
The confined accessibility of the antibodies to the cell surface enabled data to be gained on a 
possible transport of the galectin to the extracellular area of the cell membrane. 
Figures 12 - 14 illustrate representative results of the FACS analyses. 
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Figure 12: FACScan analysis. Reactivity using anti-gal-1 IgG as primary reagent. Light gray line (WT 
and Mock): response without anti-gal-1 IgG or IgG-FITC conjugate; thin black line: response without 
anti-gal-1 IgG; thick black line: response with anti-gal-1 and IgG-FITC-conjugate; dark gray line 
(gal-1-cDNA-transfected cell lines): response of mock-treated clone for comparison. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: FACScan analysis. Reactivity using anti-gal-2 IgG as primary reagent. Light gray line (WT 
and Mock): response without anti-gal-2 IgG or IgG-FITC-conjugate; thin black line: response without 
anti-gal-2 IgG; thick black line: response with anti-gal-2 and IgG-FITC conjugate; dark gray line 
(gal-2- cDNA-transfected cell lines): response of mock-treated clone for comparison. 
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Figure 14: FACScan analysis. Reactivity using anti-gal-7 IgG as primary reagent. Light gray line (WT 
and Mock): response without anti-gal-7 IgG or IgG-FITC conjugate; thin black line: response without 
anti-gal-7 IgG; thick black line: response with anti-gal-7 and IgG-FITC conjugate; dark gray line 
(gal-7-cDNA-transfected cell lines): response of mock-treated clone for comparison. 
Table 8 expresses representative data obtained by FACS analysis in numerical values. 
Anti-gal-1, anti-gal-2 and anti-gal-7 IgG reactivity is given in the top, middle and bottom 
groups, respectively. The first number in each field represents the mean fluorescence assayed 
after incubating the samples with primary and secondary antibodies. The reactivity profile is 
illustrated in figures 12 to 14. The response was also evaluated after incubating the samples 
without the primary antibody against the respective galectin protein, but with the IgG-FITC-
conjugate (negative control). The percentage of the area beneath the peak reflecting the 
amount of galectin, without the overlapping portion beneath the peak of the negative control, 
is added in parentheses as the second value in each field. This value represents the percentage 
of positive cells in the sample. 
Mock WT 
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Anti-gal-7 
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Table 8: FACScan analysis. Anti-gal-1, -2 and -7 reactivity of HCT-15 WT, mock-treated and gal-1-, 
gal-2- and gal-7-cDNA-transfected cells. 
 WT Mock G1 17w G1 35m G1 72s 
Anti-gal-1 20 (15 %) 17 (22 %) 27 (39 %) 22 (50 %) 28 (63 %) 
      
 WT Mock G2 27w G2 21m G2 18s 
Anti-gal-2 14 (13 %) 9 (13 %) 15 (29 %) 10 (13 %) 8 (13 %) 
      
 WT Mock G7 19w G7 13m G7 2s 
Anti-gal-7 29 (18 %) 15 (14 %) 44 (80 %) 61 (87 %) 57 (86 %) 
Cell surface staining of the HCT-15 cells using anti-gal-1 IgG was analyzed. The response of 
the WT and mock-transfected cells was indistinguishable from the negative controls. All of 
the galectin-overexpressing clones had an increased level of reactivity compared to the mock-
transfected cells. This was highest in the clone 72s, followed by the clone 17w and 35m.  
Anti-gal-2 IgG was then used as primary reagent for cell surface staining. The obtained data 
showed no sign of cell surface expression of galectin-2. When assessing anti-gal-7-reactivity, 
WT and mock-control cells showed no extracellular staining. The galectin-7-overexpressing 
cells, however, demonstrated a clearly increased intensity of fluorescence. The antigen-
independent signal of cells was very low in all cell types. The fluorescence profile of the 
transfectants revealed sharp and nearly symetric peaks with a mean average of fluorescence 
around three to four times that of mock. This indicated transport of galectin-7 to the 
extracellular surface of the cell membrane.  
FACS analysis revealed clear variations in the distribution profiles of the three overexpressed 
galectins in the HCT-15 cells. This result prompted further analysis to address the following 
aspects: a.) the relative number of cells with detectable amounts of the respective galectin 
protein; b.) associations between galectin overexpression and cell size or c.) associations 
between galectin overexpression and signs of proliferation; and d.) the cellular localization of 
galectins-1, -2 or -7. The method of choice to provide the answers was immunocytochemical 
analysis. This procedure was combined with cytomorphological assessment of the cells. 
4.1.6 Immunocytochemical Analysis 
In this study part galectin-cDNA-transfected cells were not only assessed 
immunocytochemically, but also cytomorphologically. HCT-15 WT, mock-transfected, 
galectin-1-cDNA-transfected clone 72 s, galectin-2-cDNA-transfected clone 18s and 
galectin-7-cDNA clone 2s were subjected to this processing. First, fixed cell populations of 
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clones were stained with antibodies reactive with the respective overexpressed galectin 
protein and then counterstained with the DNA fluorochrome DAPI. In the preceding 
evaluation of DNA/RNA and galectin protein in ECL blots and FACScan, HCT-15 WT and 
mock-transfected cells showed basal amounts of galectin-1. However, there were no signs of 
galectin-2 or galectin-7 presence in these cell types. Therefore, WT and mock-transfected 
cells were included in the assays of galectin-1 detection. As expected, only very few of the 
WT and mock-transfected cells showed a slight reactivity towards the anti-gal-1 antibody. 
Cells transfected with cDNA specific for galectins-1, -2 or -7, respectively, showed 
significant levels of staining when incubated with antibodies directed to the respective 
overexpressed galectin. Comparison of the reactive cells of the three clones revealed clearly 
visible differences. Anti-gal-1- and anti-gal-7-positive areas were larger but less intense than 
those stained by the anti-gal-2 antibody. Representative results are shown in figure 15. The 
cells displayed the column A1 - E1 were stained with anti-gal-antibodies. The first label in the 
upper right corner of these images written in capital letters describes the cells analyzed. The 
specificity of the used antibody is then described in small letters. The microphotographs in the 
column A2 - E2 show the respective cells, their nuclei being counterstained with DAPI. 
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Figure 15. Detection of gal-1 (A1-C1), gal-2 (D1) and gal-7 (E1) in WT (WT) HCT-15 cells (A1), 
Mock-treated cells (B1), and cells transfected with cDNA specific for gal-1 (C1), gal-2 (D1) or gal-7 
(E1). The nuclei of the same cells were counterstained with DAPI (A2-E2). An example of a cell 
after detection of galectin and staining with DAPI is marked with arrow. Bar is 50 µm. 
GAL-7/gal-7 
GAL-2/gal-2 
GAL-1/gal-1 
MOCK/gal-1 
WT/gal-1 DAPI 
DAPI 
DAPI 
DAPI 
DAPI 
A1 
B1 
C1 
D1 
E1 E2 
D2 
C2 
B2 
A2 
Results and Discussion 
 
62 
Next, cells were counted and stained with an antibody against the respective overexpressed 
galectin. By this method, the percentage of galectin-positive cells in clones resulting from 
each transfection was determined. Five hundred of the fixed cells on the slides were randomly 
chosen and their staining was evaluated. Results showed that the frequency of positivity was 
highest in galectin-2-cDNA transfectants with 79 %, followed by galectin-7-cDNA 
transfectants with 67 % positivity. The lowest fraction of positivity was 53 % assayed in the 
galectin-1-cDNA transfectant. These results are illustrated in figure 16. 
 
 
Figure 16. Proportion of HCT-15 cells positive for distinct galectins-1, -2, or -7 after transfection 
with their cDNA. 
In this assay, the number of galectin positive and negative cells was determined. A question to 
be answered was whether these two cell pools had distinct characteristics. This question was 
addressed in the following procedure. Cells were not only divided into the two groups of 
positive and negative in respect to anti-gal-1, -2, or -7 staining, but these two groups were 
also divided into subgroups regarding the size of the cells. The data are set into relation to 
delineate, if possible, any association of the two parameters. The results of this assay are 
shown in figure 17. Cells are grouped according to staining and cell diameter. The number of 
cells negative for the galectin encoded in the transfected gene is shown in white columns and 
the number of positive cells in grey columns. Transfection of cDNA specific for galectin-1 
and -7 induced formation of positive large-sized cells. Transfection of cDNA coding 
galectin-2 led to large cells negative for galectin-2, whereas the positive cells were 
predominantly rather small in cell diameter. 
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Figure 17. Size distribution and antibody reactivity of cells overexpressing galectins. The x-axis 
denotes cell diameter in [µm] and the y-axis cell number in [%] among positive and negative cells. 
Top: HCT-15 gal-1-cDNA-transfected clone 72s; middle: HCT-15 gal-2-cDNA transfected clone 
18s; bottom: HCT-15 gal-7-cDNA transfected clone 2s. 
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Large cells were seen among the galectin-7-overexpressing cells, which showed staining 
patterns with obvious reactivity around the nucleus. These cells were subjected to further 
analysis. A representative image of a large cell positive for galectin-7 as frequently seen on 
slides is shown in figure 18. Cells were stained with an anti-gal-7 antibody, and the same cells 
were counterstained with DAPI. The diameters of the areas with the highest reactivity in both 
images were then compared with each other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Typical example of a large cell positive for galectin-7 after the transfection of cDNA 
specific for this galectin. Interestingly, the nuclear area positive for galectin-7 (A) is larger than the 
area where DNA was stained with DAPI (B), which was verified by the measurements of 
fluorescence profiles (C). Bar is 50 µm. 
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After processing with anti-gal-7, both cytoplasm and nucleus of the cells were positive. 
Following subsequent counterstaining with DAPI, there were differences regarding the 
diameter of the stained area around the nucleus. The anti-gal-7-reactive area was significantly 
larger in diameter than the DAPI reactive area. The size difference of DAPI and anti-gal-7 
staining around the nucleus was also determined by measurements of the fluorescence 
profiles. No sign of nuclear shrinkage was seen that could otherwise explain this observation. 
The Ki-67 nuclear antigen is present in the S, G1, G2, and M phase of the cell cycle, but is 
absent in the G0 phase. Immunostaining with a monoclonal antibody directed against the Ki-
67 antigen therefore provides a means of rapidly estimating the proliferative active fraction of 
normal and neoplastic human cell populations 119. By double-staining the cell clones in this 
assay with distinct antibodies directed towards Ki-67 and the respective overexpressed 
galectin, one could see a sign of correlation between galectin positivity and proliferation. 
Microphotographs of HCT-15 cells treated by this protocol are displayed in figure 19. 
 
Figure 19. Comparison of expression of galectin-1 (A, B, green signal), -2 (C, green signal) and -7 
(D, green signal) and proliferation marker Ki67 (A-D, red signal) in WT (A) HCT-15 cells and the 
same type cells transfected with gene encoding galectin-1 (B), galectin-2 (C) and galectin-7 (D). 
Bar is 50 µm. 
The proportion of Ki-67-positive cells was higher in WT cells than in transfected cells. Small 
and galectin-negative cells were more frequently positive for Ki-67 than large galectin 
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positive cells. This is an implication of galectins-specific effects, influencing both 
morphology and proliferation activity. In this assay, galectin-expressing cells were larger than 
negative cells of the same clone. Furthermore, positive cells seemed to have a lower rate of 
cell cycle progression than cells in which no galectin staining occurred. In the following 
assay, a further aspect of the consequences of galectin overexpression was dealt with by 
regarding the morphology of the HCT-15 cells. 
4.1.7 Morphology 
After evaluation of the transfected cell lines with RT-PCR, ECL blot processing, 
cytohistochemical and FACS analyses, the key question of the consequences of ectopic 
proto-type galectin expression was addressed. 
Figure 20 documents representative images of the HCT-15 WT, mock-transfected cells and 
the galectin-1-, galectin-2- and galectin-7-cDNA-transfected cell clones, respectively, that 
showed the highest galectin content in the ECL reaction (see 4.1.3). As seen in these 
microphotographs, mock- and all galectin-cDNA-transfected cells had a distinctive 
appearance compared to the WT cells. It was not possible to spot obvious differences between 
the mock, galectin-2 or galectin-7 transfectants. When observing the galectin-1 transfectants, 
cells which had lost contact to the substratum and large cells with prominent vacuoles were 
seen more often than in the other cell phenotypes. 
After assessing morphological parameters, the question was addressed as to whether galectin 
overexpression can lead to an alteration of growth characteristics. For this purpose, the culture 
conditions can be adjusted to focus on different facets of cell growth. Basically, culture 
conditions for cell growth can be divided into two main categories: anchorage-independent 
growth, where cells proliferate while suspended in semisolid medium, and anchorage-
dependent growth, where cells grow with contact to a substratum. In the following step, 
anchorage-independent growth was analyzed in the methylcellulose assay.  
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Figure 20. HCT-15 cell morphology. a. WT 
cells; b. mock-transfected cells; c. gal-1-cDNA-
transfected clone 72s; d. gal-2-cDNA-
transfected clone 18s; e. gal-7-cDNA-
transfected clone 2s. Snapshots were 
performed by a SAMBA 2005 computer-
assisted microscope system with a x 20 
(aperture 0.50) magnification lens. 
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4.2 Comparative Assays 
4.2.1 Methylcellulose Assay 
Anchorage-independent growth is one of the most important features correlated to 
tumorigenicity 113. To assess growth characteristics of HCT-15 transfectants under anchorage-
independent conditions, the cells were grown in semisolid medium. The gel-like state of the 
medium was achieved by addition of methylcellulose. After culturing the cells for 10 days, 
the number of colonies that had developed were determined. Figure 21 shows the obtained 
data as a bar diagram with the average values of three independent experiments and the 
standard deviations. 
The behavior of the mock-transfected cells was compared to that of the WT cells, gal-1-
cDNA-transfected clone 72s, gal-2-cDNA-transfected clone 18s and gal-7-cDNA-transfected 
clone 2s. In average, cell populations overexpressing galectins-1, -2 and -7 developed less 
colonies under anchorage-independent conditions than the mock-transfected control cells. The 
p-values resulting from the comparison between mock and galectin-1- (p = 0.357), galectin-2- 
(p = 0.243) and galectin-7- (p = 0.279) overexpressing cells showed that the differences were 
not significant. 
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Figure 21. Colony formation assay in methylcellulose supplemented medium. 
Number of colonies of mock-transfected cells (Mock) was compared with those of 
WT cells (WT), gal-1-overexpressing clone 72s (Gal-1), gal-2-overexpressing 
clone 18s (Gal-2) and gal-7-overexpressing clone 2s (Gal-7). Values represent 
means ± SD of three independent experiments. 
Setting these data into relation to evidence in literature, it is noteworthy that the gene 
encoding galectin-7 belonged to one of only 14 out of 7202 genes, of which transcription was 
upregulated before the onset of p53-induced apoptosis 99. This was evaluated in studies by 
Polyak et al. with the colorectal cancer line DLD-1, containing an inactive endogenous p53 
gene. These cells were infected with a replication-defective adenovirus encoding p53, 
resulting in induction of apoptosis. The property of p53 reaching highest levels of 
reproducibility is its ability to activate transcription of genes. The transcripts induced by p53-
expression before the onset of apoptosis were examined in detail. The upregulation of 
transcription of the galectin-7-encoding gene was recognized by referring to it as p53-induced 
gene 1. 
Galectin-7 was originally identified after systematic analysis of keratinocyte proteins using 
two-dimensional gel electrophoresis 120. The feature of it being a protein highly down-
regulated in SV40-transformed keratinocytes attracted the attention of the researchers, whose 
aim was to spot respective markers. Of special interest here, Ueda et al. performed a study 
with cells of the colon carcinoma line DLD-1 stably transfected with galectin-7-cDNA 121. 
Their aim was to examine the influence of galectin-7 overexpression on tumor growth. 
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Anchorage-independent growth was assessed by culturing the cells in soft agar for 21 days. 
Thereafter, the cells were stained and the colonies were counted. They report that a 
significantly lower number of colonies formed from the galectin-7 transfectants than the 
mock-transfected control cells. However, these results should not be extrapolated because the 
following influences may have a bearing on the outcome of the assay:  type of cell line, 
experimental parameters and the extent of galectin-7 overexpression. Combining knowledge 
on signaling routes and corresponding galectin effects may provide clues for further 
experiments. 
Growth under anchorage-independent conditions has been demonstrated to be under the 
influence of the phosphatidylinositol 3-kinase pathway 122, 123, 124. There is a direct connection 
between a galectin and this pathway. Of particular relevance for our context, Elad-Sfadia et 
al. have described the intriguing ability of intracellular galectin-1 to bind to and activate the 
oncogenic small GTPase H-Ras, which plays a pivotal role in the development of 
malignancy 125. This interplay was independent of the extracellular sugar binding functions of 
galectin-1. The obtained data point to an activating interaction, which involves insertion of 
the farnesyl moiety of Ras into a hydrophobic pocket of galectin-1. This explains the 
disruption of the bond between the constitutively active H-Ras(G12V) with galectin-1 by the 
farnesylcysteine mimetic farnesylthiosalicyclic acid 88. This hypothesis was tested by a 
rationally designed galectin-1 (L11A) mutant 126. In this study, a hydrophobic pocket in 
galectin-1 was identified, sharing sequence and secondary structural motifs with the Cdc42 
geranylgeranyl-binding cavity in RhoGDI. The mutation was set on L11 of galectin-1 because 
of the importance of its L77 homologue in RhoGDI in isoprenoid-binding. The galectin-1 
(L11A) mutant possessed normal carbohydrate-binding capacity and homodimerization 
properties but selectively inhibited Ras-GTP. The interaction of galectin-1 with H-Ras has 
been shown to not only augment the activation of H-Ras but also to confer specificity to 
H-Ras by diverting its signals to Raf-1 at the expense of phosphoinositide 3-kinase.  
Diverting signals away from the phosphoinositide 3-kinase pathway through galectin-1 
influence could lead to inhibition of anchorage-independent growth. In the present study, the 
average number of colonies was lowest in galectin-1-overexpressing cells, though the p-value 
comparing the differences to mock-control went beyond the standard level defining 
significance. Further experiments are necessary to determine the influence of the 
phosphoinositide 3-kinase pathway in galectin-overexpressing HCT-15 cells. After closely 
examining anchorage-independent growth characteristics, the next step was to analyze growth 
under anchorage-dependent conditions. 
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4.2.2 Doubling Time 
A hallmark of cancer cells is their accelerated growth rate. To date, correlations have been 
identified between the influence of nuclear (Lin et al.) and exogenous (Sharma et al.) 
galectin-3, the early cell cycle regulator cyclin D1, and enhanced cellular proliferation 127, 128. 
Beyond galectin-3, though, very little was known of influences other members of the galectin 
family can have on cell cycle progression. While this work was in progress, a novel growth-
regulatory mechanism of galectin-1 was described by Fischer et al.  129. Therefore, the 
possible effect of the overexpression of galectins-1, -2, or -7 in HCT-15 cells on the rate of 
cell division was analyzed in the present study. This was carried out by plating 5 x 104 cells in 
each well of a 24-well plate. The cell numbers that emerged from this initial seeding were 
determined on days 3 through 6 in 24 hour intervals. The average values of the cell counts 
from three independent experiments are displayed in figure 22. 
 
Figure 22. Evaluation of the cell number on days 3 through 6. HCT-15 cells were counted in 24 h 
intervals, 72 to 144 h after initial seeding. The results of WT (WT), mock (Mock), gal-1-cDNA-
transfected clone-72s (Gal-1), gal-2-cDNA-transfected clone-18s (Gal-2) and gal-7-cDNA-
transfected clone 2s (Gal-7) are displayed as mean growth curves. Data was gained in three 
independent experiments. 
After careful evaluation of the gained data, the growth statistics were interpreted as the 
doubling time of the cells. The doubling time of the mock-transfected cells was compared 
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with that of the WT cells, and the cells overexpressing galectins-1-, -2- and -7, which is 
displayed in figure 23. 
 
Figure 23. Doubling time. Doubling time of HCT-15 mock-transfected cells (Mock) was 
compared with that of WT cells (WT), gal-1-cDNA-transfected clone 72s (Gal-1), gal-2-
cDNA-transfected clone 18s (Gal-2) and gal-7-cDNA-transfected clone 2s (Gal-7). 
Results represent means ± SD of three independent experiments. 
Whereas the individual values of the mean doubling time of the transfected cell clones all 
ranged closely around 26 hours, the WT cells showed a doubling time of 39 hours. After 
statistically processing the data, the p-value of the comparison of this parameter gained from 
the WT cells compared to the mock-transfected cells was just above the limit of being 
significant (p = 0.051). In this experimental model and under the given conditions, 
overexpression of galectins-1, -2 or -7 showed no impact on the doubling time of the cells 
compared to the mock control. There are studies described in the literature, however, that 
show unambiguous evidence of growth-regulatory effects caused by galectin-specific 
interactions. 
Of note in respect to the present study, Fischer et al. addressed the question as to whether 
colon carcinoma and other carcinoma cells are susceptible to growth regulation by 
galectin-1 129. Experiments were performed on a panel of eight human epithelial cell lines 
including hepatoma, melanoma as well as colonic, breast, pancreas and ovarian carcinoma 
cell lines. Exogenous treatment of the cells with galectin-1 resulted in growth inhibition of six 
of the eight cell lines, as recorded by counting the number of cells that had proliferated after 
p=0.051 
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4 days. The two cell lines that did not show this sensitivity were the colonic carcinoma cell 
lines HT-29 and Caco-2. Sugar-dependency of the growth inhibitory effect was indicative of 
the involvement of glycosylated regulators of cell growth, which were accessible to the 
galectin-1 added in the medium. Integrins as glycosylated membrane proteins, which act as 
salient translators of both inside-out and outside-in signaling, have these attributes 130. 
Therefore, the integrin expression profiles of cell lines responsive and of those resistant to the 
exogenous galectin-1 treatment were evaluated by flow cytometry and compared to one 
another. Indeed, the presence of a distinct integrin was found that correlated with galectin-1 
responsiveness. This was the α5 integrin, which associates with β1 integrin to the α5β1 
fibronectin receptor. Further experiments with integrin ligands and neutralizing antibodies 
directed towards different integrins proved a specific functional relationship between the α5β1 
fibronectin receptor and the growth inhibitory effect of exogenous galectin-1. This was 
substantiated by stably transfecting both α5-deficient colon cancer cell lines with a cDNA 
encoding the α5 integrin subunit. This conferred galectin-1 responsiveness, resulting in 
growth inhibition. The molecular mechanisms of the growth inhibitory effect were delineated 
in a stepwise manner in galectin-1-responsive HT-29α5 cells expressing α5 integrin. Flow 
cytometric analysis of DNA content demonstrated that galectin-1 treated cells were retained 
in the G1 phase, notably without signs of an increased rate of apoptosis. This was a 
consequence of the inhibition of cyclin-dependent kinase Cdk2 activity, which was shown to 
follow galectin-1 treatment. An explanation for Cdk inhibition was searched for by 
assessment of Cdk2 regulatory proteins. This monitoring revealed that the quantity of p21 and 
p27, which bind to and inhibit Cdk2/cyclin complexes, was higher in cells when galectin-1 
was added to the medium. On the one hand, this was a result of enhanced protein stability of 
p27. The protein half-life was selectively prolonged in cells incubated with galectin-1. To 
address the next possibility of increasing protein content, transcription levels of luciferase 
reporter constructs with the promoter regions of p21 and p27 were determined. Transcription 
of the p21 and p27 reporter constructs were both upregulated by galectin-1 treatment.  
To analyze transcriptional activation of p27 in detail, promoter elements that convey 
galectin-1 responsiveness were made out by deletion analysis of the p27 promoter. This 
revealed two GC-rich boxes as putative binding sites for Sp-like transcription factors. Further 
mutational analysis confirmed these to be accountable for galectin-1-specific upregulation of 
transcription. Ongoing analysis demonstrated galectin-1 to specifically and selectively 
stimulate the binding of Sp1 and Sp3 to the identified galectin-1 responsive element of the 
p27 promoter. While the cellular and nuclear content of Sp1 or Sp3 on blots was not altered 
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by galectin-1 treatment, the enhanced binding of Sp1 was found to be a result of 
posttranslational modifications, regulating its transactivating properties. Phospho-specific 
antibodies revealed that the relative amount of phosphothreonine was substantially reduced by 
galectin-1, which was then responsible for increased binding of Sp1 to the p27 promoter.  
As the extracellular signal-related kinase (ERK) is a potential modulator of Sp1 
phosphorylation, its activity was assessed using a phospho-specific ERK antibody in relation 
to galectin-1 treatment. The activity, but not the expression levels, of ERK was suppressed by 
galectin-1 in HT-29α5 cells. Importantly, this was not the case in α5-deficient HT-29 cells. 
This indicated that the modulation of ERK activity was due to interaction of galectin-1 with 
glycans of the α5β1 fibronectin receptor. As expected, the activity of the immediate upstream 
ERK1/2 kinase MEK was inhibited, as determined by reduced binding of phospho-MEK-
specific antibodies. A connection still had to be made between the interaction of galectin-1 
with α5β1 integrin and the activation of MEK. The small GTPase Ras was the potential 
missing link because of its role as an upstream regulator of ERK and regulation by α5β1 
integrin. The Ras-binding domain of Raf selectively precipitates GTP-bound active Ras. It 
can therefore be used as a tool to separate the active Ras fraction from the inactive GDP-
bound fraction. By subsequent quantification of the bound Ras protein in immunoblots, the 
activity level can be determined. This was performed in the described study and Ras 
activation was indeed shown to be virtually abolished in galectin-1-treated cells. The scheme 
of galectin-1-mediated growth inhibition is depicted in figure 24. The indicated method of 
action of galectin-1 was tested at different checkpoints. As briefly mentioned above lactose, 
fibronectin and specific α5β1-blocking antibodies interfered with galectin-1/α5β1 interactions 
extracellularly and blocked the growth inhibitory effect. At the intracellular level, 
constitutively active Ras and MEK were no longer inhibitable by galectin-1 and the 
transcriptional induction of the p27 reporter gene construct was no longer observed. The 
specific MEK inhibitor PD 98059 on the other hand, mimicked galectin-1 effects as 
demonstrated by reduced threonine phosphorylation on Sp1, increased binding of Sp1 and 
Sp3 binding to the p27 promoter, increased cellular p27 content and G1 cell cycle inhibition. 
Transfection of a dominant negative MEK variant (MEK S222A) as well as the presence of 
PD-98059 resulted in p27 promoter induction, similar to the effect of galectin-1.  
In summary, evidence was found that galectin-1 binding to α5β1 integrin inhibited the 
Ras-MEK-ERK signaling cascade, which relieved the ERK-dependent suppression of Sp1 
activation and induced Sp1-dependent p27 gene transcription and protein stability. The 
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cyclin-dependent kinase inhibitor p27 then blocked Cdk2 activity and subsequent G1/S cell 
cycle progression, which ultimately led to growth inhibition 129. 
This study presents a new and exceptionally well-defined mechanism of growth inhibition 
induced by the specific interaction of a galectin-1 on the cell surface. This was triggered after 
the key interaction of galectins and integrins. In addition to their adhesive function, integrins 
also initiate and modulate signal transduction cascades. Both ligand occupancy and integrin 
clustering are critical for the activation of integrins and trigger intracellular signaling 
cascades 131. The proto-type galectins-1, -2 and -7 with their dimeric character have the 
potential to modulate the ligand occupancy and clustering of integrins. Changing the point of 
view, the accessibility, composition and conformation of the glycan chains attached to the 
integrins in the molecular (glyco-)environment on the cell surface can be adjusted. These 
parameters have the capability of influencing galectin binding and therefore control galectin-
responsiveness. And indeed this is not only hypothetical as there are data providing evidence 
for variant glycosylation as a regulatory mechanism for β1 integrins 132. Further research is 
certainly necessary to infer in which way galectins fit into this compelling regulatory network. 
Results and Discussion 
 
76 
 
Figure 24. Scheme of galectin-1 mediated growth inhibition via transcriptional induction of the p27 
gene promoter. Functional interaction of galectin-1 with fibronectin receptor α5β1 inhibits the 
Ras-MEK-ERK signaling pathway resulting in reduced threonine-phosphorylation of Sp1, increased 
Sp1 transactivation and DNA binding and consecutive induction of p27 gene transcription. 
Accumulation of p27 inhibits Cdk2 activity and ultimately results in G1 cell cycle arrest and growth 
inhibition. Galectin-1-mediated effects on most steps within the cascade can be either blocked (    ) 
or mimicked (     ) as indicated. For reasons of simplicity, galectin-1-induced p21 transcription is not 
included in the scheme. From Fischer et. al. (2005) 129. 
Gal-1 interaction 
with α5β1 
Inhibition of 
Ras activity 
Inhibition of 
MEK activity 
Inhibition of  
ERK 1/2 activity 
Decreased Thr-
phoshphorylation 
of Sp1 
Increased DNA 
binding of Sp1 
Increased Sp1 
transactivation 
Increased p27 
transcription 
 
Increased p27 
sequestration 
 Decreased  
Cdk2 activity 
 
G1 arrest 
GROWTH 
INHIBITION 
Lactose 
Fibronectin 
anti-α5β1 
Lactose 
Fibronectin 
anti-α5β1 
Constitutively 
active Ras 
Constitutively 
active MEK 
PD 98059 
PD 98059 
Dominant 
negative MEK 
Results and Discussion 
 
77 
Noteworthy for the present study and as mentioned above, Sturm et al. inferred cell lines of 
different origin to be responsive to the growth-inhibitory effect of galectin-1, underlining the 
importance of the described results 78. The two out of eight cell lines that did not react in the 
same manner were the colonic carcinoma cell lines included in the assay. Differences in the 
experimental conditions, i.e. the exogenous addition of galectin-1 to the medium as opposed 
to the ectopic overexpression, constitute unbridgeable gaps that prohibit extrapolations to the 
present study. Still, data gained in FACScan analysis (see 4.1.5) demonstrated the transport of 
galectin-1 to the cell surface, where functional cis- or trans- interactions with glycan chains 
are plausible. Therefore, comparison between the two studies is justified. It is appealing to 
correlate the lack of responsiveness to galectins-1, -2 or -7 of the colonic carcinoma HCT-15 
cells with the absence of regulatory integrins, as described above for the cell lines HT-29 and 
Caco-2 that are of the same origin. Indeed, loss of either galectin-1 or α5β1 integrin 
expression, which have been described during the process of malignant transformation in a 
variety of tissues 133, 134, would relieve galectin-1 restriction of cell cycle progression and 
thereby favor epithelial tumor cell growth. Further experiments evaluating the integrin profile 
of the HCT-15 cells could contribute to the understanding of sensitivity and resistance to 
growth-regulatory mechanisms and be of significant clinical relevance.  
Having documented cell proliferation by manually counting cells, another method was chosen 
characterizing anchorage-dependent growth. To allow a large number of assays to be 
processed, a further system meeting this requirement was applied. In detail, this method will 
be introduced at the beginning of the next section. 
4.2.3 MTT Assay 
The MTT assay is a versatile method to analyze cell growth characteristics satisfying the 
requirements given above. Anchorage-dependent growth was evaluated under different 
experimental conditions with varying serum content of the medium. The experimental series 
began with measuring the response of the cells kept under the standard cell culture conditions 
as described in 3.3.2, regarded to be optimal for cell growth. 
4.2.3.1 Cell Growth After Four Days 
Growth characteristics of HCT-15 cells were measured after seeding 2,000 cells into the wells 
- five for each cell clone - of a 96-well plate, which was incubated for 4 days at 37 °C. Then, 
the concentration of dye produced by viable cells after 4 hours of incubation with an MTT 
solution was photometrically measured in an ELISA minireader. The data in figure 25 
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represent means of six independent experiments with mock-transfected, WT cells, the 
galectin-1-cDNA-transfected clone 72s, the galectin-2-cDNA-transfected clone 18s and the 
galectin-7-cDNA-transfected clone 2s including the respective levels of standard deviation. 
The galectin-1-cDNA-transfected clones 17w and 35m were included in the last two 
experiments in order to illustrate any quantity-dependent effects of galectin-1 in the cells. The 
data of these two clones shown in figure 25 represent average values of two 
experiments ± SD. 
 
Figure 25. MTT assay 4 days after seeding. Response of HCT-15 mock-transfected cells (Mock) 
was compared with that of WT cells (WT), gal-1-cDNA-transfected clones 17w (G1 17w), 35m 
(G1 35m) and 72s (G1 72s), gal-2-cDNA-transfected clone 18s (G2 18s) and gal-7-cDNA-
transfected clone 2s (G7 2s). The p-values ≤ 0.05 are displayed above the respective column. 
Numbers represent means ± SD of six (Mock, WT, G1 72s, G2 18s, G7 2s) or two (G1 17w, 
G1 35m) independent experiments. 
Differences were seen by comparing data of the mock-transfected clone with values obtained 
from the WT cells and from each of the other clones. The response of the galectin-1-
overexpressing clone 72s was less than that of the mock-transfected clone in nearly every 
experiment. The differences were significant with a p-value of 0.037. The galectin-7-
overexpressing clone 2s also had lower values than cells after mock treatment. The p-value 
resulting from the comparison of data from this clone with the data obtained from the mock-
transfected cells was close to the level of significance (p = 0.0559). The reactivity of the WT 
p=0.037 
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cells and the galectin-2-cDNA-transfected clone 18s was comparable to that of the mock-
transfected cells. Their p-values were 0.427 and 0.715, respectively. 
Overexpression of galectin-1 appeared to have an effect on the response of this assay. This 
will be substantiated if other galectin-1-overexpressing clones behave similarly. Therefore, 
clone 17w and clone 35m that had a “weak” and “medium” response in the ECL blots 
evaluating the galectin-1 content, respectively, were included in the assay. Neither was 
significantly different than the mock-transfected cells. But, as shown in figure 25, the 
reduction of the signal intensity relative to the mock-transfected cells corresponded directly 
with the protein content of the clones assayed in the ECL blots. This result is an indication for 
a quantity-dependent effect of galectin-1. 
There are three possibilities to explain the obtained results. These are a.) retardation of cell 
growth, b.) cell death, or c.) a combination of both reactions. These two separate processes 
have already been related to galectin-dependent effects after addition of the lectin to the 
medium of cells in other cases. Kopitz et al. observed decreased neuroblastoma cell growth as 
an effect of carbohydrate-dependent cell surface binding of galectin-1 77. The increase of cell 
density of the cultured neuroblastoma cells (SK-N-MC) went along with an increase of the 
cell surface ganglioside sialidase activity. This sialidase is responsible for a shift from higher 
gangliosides toward GM1 - the preferential ligand of galectin-1 76. Noteworthy for a 
comparison to the present study, the increase of cell surface ganglioside sialidase activity also 
coincided with a higher amount of galectin-1 cell surface expression. Maximum levels were 
reached when the growth kinetics of the cell population normally underwent the transition to 
density-dependent inhibition of proliferation. When galectin-1 was exogenously added to the 
medium and incubated with the cells for 48 hours, the cell number decreased in a 
concentration dependent manner. The data thus indicate that galectin-1 is an effector in the 
sialidase-dependent growth control in this system. Neither was the reduction of cell 
proliferation influenced by caspase inhibitors, nor was DNA fragmentation detected, making 
it unlikely that galectin-1 exerted its effects by acting as a classical proapoptotic factor on 
these cells. Interestingly, galectin-7 triggered identical responses in following comparative 
studies, in which the effects of exogenously added galectin-7 were evaluated in this 
experimental system 135. Again, the sugar chain of the ganglioside GM1 was identified as a 
ligand for galectin-7. Similarity in ligand selection between galectins-1 and -7 should be 
reflected on a structural level. Indeed, Leonidas et al. analyzed the crystal structure of 
galectin-7 in free and carbohydrate-bound forms 91. Their data showed that although the 
architecture of the carbohydrate recognition domain and the lengths and conformation of loop 
Results and Discussion 
 
80 
regions differed relative to galectins-1 and -2, this factor will not markedly alter the 
specificity. Fittingly, Ahmad et al. showed rather similar binding data for N-acetyllactosamine 
for galectins-1 and -7 by isothermal titration calorimetry 136. Regarding the glycolipid, 
affinities of galectins-7 and -1 to the sugar chain of the ganglioside GM1 were similar 135. As a 
consequence, binding parameters of galectin-7 to the neuroblastoma cell surface was 
indistinguishable from that of galectin-1. Incubating neuroblastoma cells with galectin-7 
added to the medium led to inhibition of the proliferation of the cells 135. This occurred 
without signs of classical apoptosis such as caspase activation or DNA fragmentation. 
Comparing the described results with the data presented in this work, it must be pointed out 
that these effects were evaluated after addition of exogenously added galectins to the medium. 
However, as described in the example of galectin-1 inhibiting neuroblastoma cell growth, the 
data are conclusive that the triggered reaction is responsible for cell density dependent growth 
arrest. This involves the interaction of galectin-1 and the sugar chain of ganglioside GM1 (for 
details of interaction, please see 137). Notably, the cell surface presentation of both binding 
partners is upregulated during differentiation. As shown in FACScan analysis in the present 
study, overexpression of galectin-1 and galectin-7 resulted in cell surface presentation of the 
respective galectins. It is therefore interesting to compare the data from the present study 
evaluating cell growth after 4 days to the results of the experiments by Kopitz et al. evaluating 
the growth inhibition properties of galectins-1 and -7. Nonetheless, the differences in the 
experimental conditions using a.) ectopic overexpression, b.) exogenous addition of galectins 
to the medium and c.) different cell lines constitute substantial variations. Therefore, any 
extrapolations between the systems are not a priori valid. 
As mentioned above, the observed results of the MTT assay after 4 days can also be explained 
by an increased rate of cell death or a combination of cell death and growth retardation. Of 
particular interest in this respect, Sturm et al. describe comparative assays of the effects of 
exogenous galectins-1, -2 and -7 on activated T cells 78. Strikingly, definition of the binding 
partners of the respective galectins revealed distinct behavior. Despite the abundance of 
β-galactosides on the cell surface, galectins-1 and -2 not only targeted specific epitopes, but 
the two lectins actually did this in a qualitatively distinct manner. In contrast to galectin-1, the 
glycoproteins CD3 and CD7 were not ligands of galectin-2 on blots, while both lectins shared 
affinity to β1 integrin (CD29). This differential selection of binding partners is all the more 
noteworthy, regarding the very similar amino acid sequences of these closely related 
galectins, especially around the carbohydrate recognition domain with its central tryptophan 
residue and conservation of the set of essential residues 67, 90. Apparently, β-galactoside 
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derivatives with substitutions at the core lactose influence galectin selection of endogenous 
binding partners. This question was handled with by Ahmad et al. as already referred to 
above. In detail, they performed thermodynamic binding studies of cell surface carbohydrate 
epitopes to galectins-1, -3, and -7 136. Results showed that naturally occurring 
oligosaccharides can differ to a certain extent in ligand capacity for human galectins, as 
evaluated by isothermal titration calorimetry. Siebert et al. approached this question from a 
different angle, using a combined nuclear magnetic resonance-spectroscopical and 
computational study 137. Their aim was to illuminate the sites for binding of galectin-1 to a 
complex ligand by structural analysis of the two binding partners. They discovered that the 
pentasaccharide of ganglioside GM1 makes contacts to the binding pocket of galectin-1 
beyond the primary site accommodating the galactose moiety. This extended binding site is a 
probable explanation for the restricted binding of galectin-1 to a limited and specific set of 
interaction partners. As mentioned above, galectins-1 and -2 homed in on a specific and 
distinct set of targets on the cell surface of activated T cells. The result of this carbohydrate-
dependent interaction of galectin-2 was the induction of apoptosis 78. This involved activity of 
caspases-3 and -9 as determined by fluorogenic substrate and inhibitor assays. Surveying key 
checkpoints of the apoptotic pathway revealed cleavage of the DNA fragmentation factor, 
enhanced cytochrome c release, disruption of the mitochondrial membrane potential and an 
increase of the Bax/Bcl-2 ratio by opposite regulation of expression of both proteins. The 
investigations proved that cell death was triggered by the intrinsic apoptotic pathway. 
Monitoring of cell cycle phases by measurement of the DNA content revealed no differences 
induced by the interaction of galectin-2. Protein expression of key cell cycle regulators was 
measured by Western blotting and also showed no alteration prompted by exogenous 
galectin-2. Comparative evaluation of the effects of galectins-1 and -7 binding to the cell 
surface of activated T cells revealed remarkable deviations from the reactions caused by 
galectin-2. Both galectins-1 and -7 had proapoptotic effects, but this involved distinct profiles 
of caspase activation. Galectin-1 induced the caspases-3, -8 and -9, while galectin-7 binding 
resulted in the activation of caspases-1, -3 and -8. In other words, while apoptosis induced by 
galectins-1 and -7 involved caspase-8, this was clearly not the case after the interaction of 
galectin-2 with the T cell surface ligands. An additional significant difference in the reactions 
caused by the three proto-type galectins was revealed by analyzing cell cycle parameters. 
Flow cytometric analysis of the expression of cyclin B1 was performed because of its 
important role as an effector of cell cycle progression. Increasing concentrations of exogenous 
galectin-2 had no effect of this parameter in activated T cells. Galectins-1 and -7, however, 
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evoked a concentration dependent decrease of cyclin B1 expression, inhibiting cell cycle 
phase progression. Summing up the results of this part of the study, this is an intriguing 
example of differential binding patterns and distinct responses of proto-type galectins in the 
same experimental system. As mentioned above, a decrease of the response of the MTT assay 
after 4 days of cell growth in the present study can be a result of growth retardation, increased 
cell death or a combination of both processes. Interestingly, the reactions after cell surface 
binding of proto-type galectins as described by Sturm et al. 78 include examples of the 
induction of apoptosis by itself and also in combination with the inhibition of cell cycle 
progression. In the model colon cancer cells, further experiments with the HCT-15 
transfectants are necessary to assess cell cycle and apoptosis parameters in order to explain 
the molecular mechanisms of the measured effects. After assessment of growth behavior 
under optimal growth conditions, the question was addressed as to whether the reduction of 
supplied nutrients served as challenge to evoke galectin-specific reactions. 
4.2.3.2 Resistance to FCS Deprivation 
The MTT assay was modified to observe how the cells reacted to different growth conditions, 
specifically to see their susceptibility to suboptimal parameters. Two thousand cells were 
seeded into each of the wells of a 96-well plate and cultivated over a period of 10 days in 
medium that contained 10 %, 3 %, 2 % or 1 % FCS (v/v). The amount of viable cells was 
assessed on day 1, 3, 6, 8 and 10. The medium was not exchanged until the day of 
measurement, when the cells were incubated with the MTT solution for 2 hours at 37 °C. The 
HCT-15 WT, mock-transfected cells, galectin-1-cDNA-transfected clones 17w and 72s, 
galectin-2-cDNA-transfected clone 18s and the galectin-7-cDNA-transfected clone 2s were 
included in the assay. Three independent experiments were performed in the assays with 1 %, 
2 %, and 3 % FCS (v/v) in the medium. Four independent experiments were performed with 
10 % FCS (v/v) in the medium. The mean values of the experiments are illustrated as median 
growth curves in figures 26 to 29. 
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Figure 26. Growth curves of HCT-15 cells grown in medium with 10 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 17w (G1 17w) and 
clone 72s (G1 72s), galectin-2-cDNA-transfected clone 18s (G2 18s) and galectin-7-cDNA-
transfected clone 2s (G7 2s). Data represents means of four independent experiments. 
Figure 27. Growth curves of HCT-15 cells grown in medium with 3 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 17w (G1 17w) and 
clone 72s (G1 72s), galectin-2-cDNA-transfected clone 18s (G2 18s) and galectin-7-cDNA-
transfected clone 2s (G7 2s). Data represents means of three independent experiments. 
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Figure 28. Growth curves of HCT-15 cells grown in medium with 2 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 17w (G1 17w) and 
clone 72s (G1 72s), galectin-2-cDNA-transfected clone 18s (G2 18s) and galectin-7-cDNA-
transfected clone 2s (G7 2s). Data represents means of three independent experiments. 
Figure 29. Growth curves of HCT-15 cells grown in medium with 1 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 17w (G1 17w) and 
clone 72s (G1 72s), galectin-2-cDNA-transfected clone 18s (G2 18s) and galectin-7-cDNA-
transfected clone 2s (G7 2s). Data represents means of three independent experiments. 
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A general tendency of the WT cells in all four FCS concentrations was that they apparently 
grew faster than the transfected cells during the first days of the assay. The median growth 
curves peaked at the time around day 6, after which the number of viable cells decreased 
during the further duration of the assay. Comparing the median growth curves of the 
transfected cells, the galectin-7-overexpressing cells had the highest amount of viable cells of 
all transfectants in nearly every day of analysis. In contrast, the galectin-1-cDNA-transfected 
clone 17s often had the lowest response in the MTT assay. 
The influence of FCS content was tested and proved to have a strong influence on cell growth 
and viability. In 10 % FCS (v/v), the response of the WT cells was considerably stronger than 
the mock-, galectin-1-cDNA- and galectin-2-cDNA-transfected cells during the first 6 days of 
the assay. The largest contrast to these cells was on day 6 of evaluation, after which the 
number of viable WT cells continuously decreased until the response was lowest of all 
evaluated cells on day 10. The galectin-7-overexpressing clone 2 initially reacted very similar 
to the WT cells and produced a stronger response than all other transfectants, but unlike the 
WT cells, the response remained highest among the transfectants until finishing the assay. 
The curve representing data on viability of WT cells in 3 % FCS (v/v) clearly separated itself 
from the others by ascending at a higher angle. This continued until after day 6, when the 
response lessened and the curve converged towards those of the transfectants. The amount of 
viable cells was highest for galectin-7-overexpressing cells among all transfectants, although 
the absolute difference was not as substantial as in the assay with 10 % FCS (v/v). When the 
FCS concentration was lowered even further to 2 % and 1 % FCS (v/v) there was no 
considerable increase in viable transfected cells throughout the period of evaluation. The 
reaction of the WT cells in the MTT assay, however, did rise in 2 % FCS (v/v) during the first 
8 days of the assay. In 1 % FCS (v/v), the response of WT cells was similarly low as the other 
cells assayed. 
The values registered by examining the properties of cells grown in 10 % FCS are displayed 
as bar charts in figure 30 and represent the average means of four independent 
experiments ± SD. The response of mock-transfected cells was compared with that of other 
cells analyzed under identical conditions. The calculated p-value is written above the 
respective bar when p ≤ 0.05. On day 6 and day 10, the p-values of the data from the 
galectin-7-overexpressing clone 2 compared with that of the mock transfectant were low, but 
exceeded the limit of defining the differences as significant. They were p = 0.069 and 
p = 0.068, on day 6 and 10 respectively. 
Results and Discussion 
 
86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. MTT assay of HCT-15 cells 
seeded in 10 % FCS (v/v). The response of 
the mock-transfected cells (Mock) was 
compared with the WT cells, the gal-1-
overexpressing clones 17w (G1 17) and 72s 
(G1 72), the gal-2 overexpressing clone 18s 
(G2 18) and the gal-7 overexpressing 
clone 2s (G7 2) evaluated under identical 
conditions. The calculated p-value is written 
above the respective bar when p ≤ 0.05. 
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Statistical analyses of the data gained from seeding the cells in medium with 3 % FCS (v/v) 
revealed significant differences of WT cells and the galectin-7-overexpressing cells when 
compared to the values of mock-transfected cells. These were seen on day 8 and day 10. The 
results of these assays is displayed in figure 31 representing the average means ± SD of three 
independent experiments. The calculated p-value is given above the respective bar when 
p ≤ 0.05.  
 
 
 
Figure 31. MTT assay of HCT-15 cells seeded in 3 % FCS (v/v). The response of the mock-
transfected cells (Mock) was compared with the WT cells, the gal-1-overexpressing clones 17w 
(G1 17) and 72s (G1 72), the gal-2 overexpressing clone 18s (G2 18) and the gal-7 overexpressing 
clone 2s (G7 2) evaluated under identical conditions. The calculated p-value is written above the 
respective bar when p ≤ 0.05. 
On day 3 of the assay with 1 % FCS (v/v), the galectin-2-overexpressing cells behaved 
significantly different to the mock-transfected cells. The calculated p-value of this comparison 
was 0.001. The average mean values ± SD are illustrated in figure 32. 
Day 8 Day 10 
p=0.029 
p=0.014 
p=0.022 
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Figure 32. MTT assay of HCT-15 cells 
seeded in 1 % FCS (v/v). The response of the 
mock-transfected cells (Mock) was compared 
with the WT cells, the gal-1-overexpressing 
clones 17w (G1 17) and 72s (G1 72), the 
gal-2 overexpressing clone 18s (G2 18) and 
the gal-7 overexpressing clone 2s (G7 2) 
evaluated under identical conditions. The 
calculated p-value is written above the 
respective bar when p ≤ 0.05. 
The primary model object of research was the HCT-15 colon carcinoma cell line. One 
question to be addressed was whether effects seen in this system were unique or could be 
valid for other colon carcinoma cell lines as well. One step in answering this question was 
made by using the DLD-1 cell line and previously established clones overexpressing 
galectin-1 and galectin-7, which had been transfected in the same manner as the HCT-15 
cells. Cells of the DLD-1 cell line were assayed under identical conditions as the HCT-15 
cells. Specifically, these were DLD-1 WT, mock-transfected cells, the galectin-1-cDNA-
transfected clone 15 and the galectin-7-cDNA-transfected clone 20. The mean values of three 
individual experiments is illustrated as median growth curves in figures 33 to 36. 
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p=0.001 
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Figure 33. Growth curves of DLD-1 cells grown in medium with 10 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 15 (Gal-1) and 
galectin-7-cDNA-transfected clone 20 (Gal-7). Data represent means of three independent 
experiments. 
Figure 34. Growth curves of DLD-1 cells grown in medium with 3 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 15 (Gal-1) and 
galectin-7-cDNA-transfected clone 20 (Gal-7). Data represent means of three independent 
experiments. 
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Figure 35. Growth curves of DLD-1 cells grown in medium with 2 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 15 (Gal-1) and 
galectin-7-cDNA-transfected clone 20 (Gal-7). Data represent means of three independent 
experiments. 
Figure 36. Growth curves of DLD-1 cells grown in medium with 1 % FCS (v/v). MTT assay of 
mock-transfected (Mock), WT (WT) cells, galectin-1-cDNA-transfected clone 15 (Gal-1) and 
galectin-7-cDNA-transfected clone 20 (Gal-7). Data represent means of three independent 
experiments. 
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The analyzed DLD-1 cells were much less sensitive to the reduction of FCS compared with 
the HCT-15 cells. The overall magnitude of the responses were similar even between the 
assays in 10 % and in 3 % FCS (v/v). Cell growth only gradually lessened in 2 % and 1 % 
FCS (v/v). 
There were noteworthy overall tendencies seen in these growth curves that were valid for the 
data gained from the four different FCS concentrations. The median values of the WT cells 
were often in a slightly higher range of optical density than the other growth curves during the 
first 6 to 8 days of analysis. The curves then slanted downward until they reached or went 
below the values of the other cells. The behavior of the galectin-1-overxpressing cells was 
almost completely the opposite. In the assays with 1 %, 2 % and 3 % FCS (v/v), the amount 
of viable cells of galectin-1-cDNA-transfected clone 15 did not increase as quickly as the 
other cells, resulting in the lowest amount of viable cells among all that were examined on 
day 6. However, this cell clone had the highest OD values in the MTT assay at the end of 
assay, regardless of the added amount of FCS in the medium. 
There were no large differences between the curves monitoring the cell viability of mock- and 
galectin-7-cDNA transfected cells in all of the assays. In general, they reached their highest 
values on day 6 and maintained these levels on the following days.  
Next, behavior specific to each FCS concentration was analyzed. In the assay in which the 
cells were seeded in 10 % FCS (v/v), the responses of the analyzed cells were all very similar 
until day 6. The curve of the galectin-1-overexpressing cells then separated itself from the rest 
and continued to rise while the others remained the same or decreased. 
In medium supplemented with 3 % FCS (v/v), the number of galectin-1-overexpressing cells 
increased at a slower rate than the other cells, but ended with the highest response on day 10. 
As was mentioned above, this behavior was also seen in 2 % and 1 % FCS (v/v). The curves 
of mock- and galectin-7-cDNA-transfected cells were almost identical in 3 % FCS (v/v). They 
increased until day 6, nearly remained at the same level on day 8 and then slightly descended 
until day 10 - the mock-transfected cells ending just below the galectin-7-overexpressing 
cells. The MTT response of the WT cells rose to an amount that was highest of the four cell 
types on day 6 and day 8, but then decreased to a level that was just below that of the 
galectin-1 overexpressing cells. This behavior of the WT cells was also seen in the assay in 
which the cells were seeded in 2 % FCS (v/v). 
In the assays, in which the FCS content of the medium was reduced to 2 % FCS (v/v), the 
curves of the mock- and galectin-7-cDNA-transfected cells were indistinguishable until day 6. 
The galectin-7-overexpressing cells then had a slightly lower response on day 8, but this 
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continued to rise on day 10, whereas the mock-transfected cells produced a response that was 
lowest of all other cell types analyzed. 
When the FCS content was decreased to 1 % (v/v) in the medium, it caused an evident 
reduction of the response. The illustrated curves ascended at a lower angle than in the 
previously described experiments. The signal of mock, WT and galectin-7-overexpressing 
cells rose until day 8. The response of mock- and galectin-7-cDNA-transfected cells on 
day 10 was almost identical to the values that had been evaluated from the respective cells on 
day 8. The signal of the WT cells, which to this point had been responsible for the highest 
values under these conditions, then produced a response that was markedly less than on day 8, 
lower than that of the other cells on that day of evaluation in the assay. As mentioned above, 
the response of the galectin-1-cDNA-transfected clone increased at a slower rate compared to 
the other cells, but ultimately surpassed that of all the other cells in the assay. 
Statistical analyses showed most significant differences of the cells compared to the mock-
transfected cells to appear on the last day of evaluation. On day 10 of the assay with 10 % 
FCS (v/v), the galectin-1-overexpressing cell clone had a significantly higher response than 
the mock-transfected cells, as illustrated in figure 37. 
 
Figure 37. MTT assay of DLD-1 cells seeded 
in 10 % FCS (v/v). The response of the mock-
transfected cells was compared with the other 
cells evaluated under identical conditions. The 
calculated p-value is written above the 
respective bar when p ≤ 0.05. 
 
 
In 3 % FCS (v/v), significant differences were seen on day 8 and day 10 in the WT and 
galectin-1-overexpressing cells. This is demonstrated in figure 38. 
p=0.014 
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Figure 38. MTT assay of DLD-1 cells seeded in 3 % FCS (v/v). The response of the mock-
transfected cells was compared with the other cells evaluated under identical conditions. The 
calculated p-value is written above the respective bar when p ≤ 0.05 
Most differences in group behavior were seen analyzing the data of the DLD-1 cells seeded in 
medium with 2 % FCS (v/v). These are displayed in figure 39.  
p=0.036 p=0.020 
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Figure 39. MTT assay of DLD-1 cells seeded in 2 % FCS. The response of the mock-transfected 
cells was compared with the other cells evaluated under identical conditions. The calculated 
p-value is written above the respective bar when p ≤ 0.05 
In 1 % FCS (v/v), only the data on cell population from the WT cells were distinct enough 
from that of the mock-transfected cells for differences to be significant. These were from 
measurements on day 1, 3 and 10 and are demonstrated in figure 40. 
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Figure 40. MTT assay of DLD-1 cells seeded 
in 1 % FCS (v/v). The response of the mock-
transfected cells was compared with the other 
cells evaluated under identical conditions. The 
calculated p-value is written above the 
respective bar when p ≤ 0.05. 
 
 
Despite the described efforts to infer a correlation between reduction in nutrient supply and 
galectin overexpression by systematic analyses, there is no obvious indication that galectin 
overexpression might have a compensatory role in this experimental system. It is clear that 
the overexpression of these galectins will not confer a marked growth advantage to the tumor 
cells under the unfavorable conditions defined in this assay. Galectins have demonstrated to 
not readily reveal specific effects such as a higher sensitivity to apoptosis-inducing agents 138. 
FCS deprivation was one stimulus to provoke galectin-specific effects. A possibility to take 
this one step further would be to assess cell viability under the influence of cell death 
inducing drugs. This was the next aim of this study. 
4.2.4 MTT Assay With Cytotoxic Drugs Added to the Medium 
Galectins are known to have an acting spectrum that can either inhibit 139, 140, 141 or enhance 
cell death 78, 100. Heterogeneous tumors are made up of cells with different levels of galectin 
content. This could lead to a varying degree of susceptibility to cancer treatment with cell 
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death inducing chemotherapeutical agents. The possible relationship of cellular galectin 
content and resistance to cytotoxic drugs was analyzed. HCT-15 colon carcinoma cells 
overexpressing galectins-1, -2 and -7 were incubated with oncologically relevant cytostatics. 
Oxaliplatin is a platinum-based drug commonly used in the treatment of colorectal carcinoma. 
The exact mechanism by which this drug is toxic to cancer cells is still being investigated, but 
broadly speaking, these molecules form adducts with cellular DNA. This process inhibits 
DNA replication and transcription, leading to apoptosis 142, 143, 144. Irinotecan and SN38 (a 
potent metabolite of irinotecan) are chemotherapeutical agents belonging to the group of 
topoisomerase I inhibitors. Topoisomerase I inhibitor-related cytotoxicity appears to be 
correlated to the induction of drug-stabilized complexes, which interfere with replication 
forks, leading to replication arrest and fork disassembly 145. 
In the assay, HCT-15 WT, mock-transfected cells, galectin-1-cDNA-transfected clone 72s, 
galectin-2-cDNA-transfected clone 18s and galectin-7-cDNA-transfected clone 2s were 
treated with four increasing concentrations of the respective cytotoxic agent for 72 hours. The 
effects were evaluated by measuring cell viability compared to a control value of the cells 
without addition of the cytostatic. Cell viability was assessed by incubation of the cells with 
the MTT solution for 4 hours at 37 °C and subsequent photometric measurement. The 
percentage of the measured optical density compared to that of the control was determined. 
This value could then be displayed in a diagram in relation to the used concentrations of the 
cytotoxic agent on a logarithmic scale. The effect of the agent was described as the 
concentration responsible for 50 % inhibition of cell viability compared to the control value 
(IC50). 
The inhibition of cell viability by the chemotherapeutical agents is illustrated in figures 41 
to 43. The curves represent the average values of data from four independent experiments. 
The IC50 was determined using the curve of each individual experiment. The mean values of 
the IC50 ± SD are displayed in figure 44. The p-values ≤ 0.05 are displayed above the 
respective bar. 
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Figure 41. Inhibition of cell viability of HCT-15 WT, mock, galectins-1, -2- and -7-overexpressing 
cells by oxaliplatin. The x-axis describes the concentration of oxaliplatin [µM] on a logarithmic scale. 
The y-axis documents the average response of the MTT assay compared to the control value of 
the cells, incubated in the absence of the cytotoxic agent (n = 4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 42. Inhibition of cell viability of HCT-15 WT, mock, galectins-1, -2- and -7-overexpressing 
cells by irinotecan. The x-axis describes the concentration of irinotecan [µM] on a logarithmic scale. 
The y-axis documents the average response of the MTT assay compared to the control value of 
the cells, incubated in absence of the cytotoxic agent (n = 4). 
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Figure 43. Inhibition of cell viability of HCT-15 WT, mock, galectins-1, -2- and -7-overexpressing 
cells by SN38. The x-axis describes the concentration of SN38 [nM] on a logarithmic scale. The 
y-axis documents the average response of the MTT assay compared to the control value of the 
cells, incubated in absence of the cytotoxic agent (n = 4). 
Results and Discussion 
 
99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 44. IC50 values of oxaliplatin (top), irinotecan (middle) and SN38 (bottom). HCT-15 WT, 
mock-, galectin-1-cDNA, galectin-2-cDNA and galectin-7-cDNA-transfected cells were assayed. 
Bars represent means ± SD of four independent experiments. p-values ≤ 0.05 are displayed above 
the respective bar. 
IC50 Values of Oxaliplatin 
IC50 Values of Irinotecan 
IC50 Values of SN38 
p=0.048 
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One unfavorable factor not to be ignored for the interpretation of the results of the assay was 
the relatively large standard deviation seen when evaluating the data. When the cells were 
incubated with oxaliplatin, the galectin-2-overexpressing cells showed a high sensitivity to the 
treatment of the cytostatic relative to the other cell types in the assay. The WT cells also had a 
comparatively low IC50 concentration, while the other examined cell types had similar 
average values. Statistically, the data sets were not significantly different to the data obtained 
with mock-transfected cells.  
Irinotecan was most effective in inducing cell death in galectin-2-cDNA-transfected cells. 
Mock-transfected cells were similarly sensitive, while higher concentrations were necessary 
to achieve the same effects on cell viability in WT, galectin-1- and galectin-7-cDNA-
transfected cells. The differences of the values to those gained from the mock-transfected 
cells were not high enough to be defined as significant. 
When SN38 was added to the medium, the reaction of the mock- and galectin-2-cDNA-
transfected cells was very similar. Observation of the behavior relative to the other cell types 
showed the WT, galectin-1- and galectin-7-overexpressing cells to be less sensitive to the 
influence of SN38. The data of the galectin-1-cDNA-transfected cells passed the level of 
significance when set into relation to those of the mock-transfected cells (p-value = 0.048). 
To date, no evidence has been presented directly linking galectin-specific effects of the 
proto-type family members with drug resistance of cancer cells to chemotherapeutical agents. 
In the present study, no irrefutable proof of such an effect could be observed. However, 
interesting results are seen in literature, which are encouraging that such a correlation could 
be discovered in the near future. Nagy et al. have associated a significant prognostic value of 
galectin-1 with colon tumors, which had been classified as Dukes A and B tumors 96. High 
levels of galectin-1 correlated with lower survival periods. Despite its known effects as a 
proapoptotic factor, high levels of galectin-7 has recently been related by Saussez et al. to a 
high recurrence rate and poor prognosis of stage IV hypopharyngeal cancer 101. 
Associations have also been made between tumor prognosis and glycostructures with 
potential impact on the galectin regulatory network. Modulation of expression of ABH 
histo-blood group antigens on tumor cells had first been described in gastric cancer by 
Masamune et al. 146. In this study, the level of expression of histo-blood group A or B epitopes 
were reduced in tumors of patients with histo-blood group A or B status. Interestingly, 
invasive and metastatic properties have been correlated with the degree of A/B deletion in 
cervical, lung, oral and bladder cancer 147, 148, 149, 150. A likely explanation for the increase in 
invasive and metastatic properties was presented in a study by Ichikawa et al.151. The 
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experiments were performed with the gastric carcinoma cell line MKN74 and the colonic 
cancer cell line HRT18. The H-antigenic determinant in A- and B-negative/H-positive 
parental cell lines was glycosylated after transfection with the cDNA encoding A or B 
transferases. This resulted in acquisition of the A- or B-positive/H-negative phenotype. 
Comparison of the transfectants with the parental cells revealed that the haptotactic motility 
was significantly reduced in the A-positive or B-positive/H-negative cells. Motility assays 
were also performed with integrin-specific monoclonal antibodies, each specific for α3, α6 or 
β1 integrin, on H-positive parental cells. These were less motile, the responses in the assay 
being similar to the effect of the altered glycosylation after A or B transfection. This revealed 
the modulated H versus A/B glycosylation of α3 or α6/β1 integrin receptor to be responsible 
for the differences in motility. This behavior was also observed in another experiment with 
the colonic carcinoma cell lines SW480 and HT29 152. A-positive and A-negative 
subpopulations, which derived from originally A-positive tumor cell lines by spontaneous 
alterations of the phenotype, were selected for these investigations. These spontaneous 
changes are a more suitable model of physiological processes than modifications induced by 
transfections. Compared to the A-positive cells, A-negative populations were characterized by 
greatly enhanced haptotactic motility associated with reduced or deleted A expression at α3, 
α6 and β1 integrin receptors. 
Changes in expression of ABH and Lewis-related histo-blood group antigens are among the 
most frequent alterations in human colon cancer 153. Accumulation of α1,2-fucosylated 
antigens including Leb and H type 2 in colorectal carcinoma has been characterized by 
Yazawa et al. 154. This investigation also implied a correlation of the expression of 
α1,2-fucosylated antigens with survival among patients with primary colorectal cancer. Of 
particular interest for the present study, α1,2-fucosylated glycan structures on colon cancer 
cells have been implicated to influence resistance to chemotherapy. Cordel et al. performed 
assays with rat colon carcinoma cells and determined molecular aspects of their acquired 
resistance to 5-fluorouracil (5-FU), which is a drug of standard use in chemotherapy of colon 
carcinoma 155. Cells resistant to 5-FU were generated by continuous exposure to the drug over 
several months. To investigate whether resistance to 5-FU was associated with a particular 
carbohydrate cell-surface phenotype, cells were processed with a panel of monoclonal 
antibodies and lectins, each specific for distinct tumor-associated carbohydrate antigens. This 
procedure revealed the antigen H type 2 to be increased. This enhanced expression was also 
accompanied by an increase in α1,2-fucosyltransferase activity, the key enzyme involved in 
the synthesis of H antigens. To test the relevance of this observation, cells devoid of this 
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enzymatic activity were transfected by an α1,2-fucosyltransferase-cDNA, which resulted in 
expression of  H type 2 antigen. As a result, these cells demonstrated an increased resistance 
to 5-FU. This relationship was further substantiated by a negative control. Cells that 
possessed enzymatic activity were transfected by a cDNA of α1,2-fucosyltransferase in anti-
sense orientation. Consequently, both H type 2 cell-surface antigen and resistance to the drug 
was reduced. The intriguing relationship between carbohydrate cell-surface phenotype and 
resistance to chemotherapy was also confirmed in the human colonic cancer cell line DLD-1 
by Yazawa et al. 156. DLD-1/5-FU-resistant cells were established by repeating continuous 
exposure of the cells to 5-FU with stepwise increases of concentration of the 
chemotherapeutical agent. Elevated expression of fucosylated antigens was found in the 
resistant cells compared to parental DLD-1 cells. Likewise, marked increases of α1,2- and 
α1,3-fucosyltransferase activities were also determined in the resistant cells. In contrast, 
α1,4-fucosyltransferase activity was found to be reduced in these cells. An interesting 
approach to modify the cell-surface glycans was chosen. Sugar acceptors for 
α1,2-fucosyltransferase - particularly β-galactosyl derivatives with hydrophobic aglycones - 
were added to the medium. This resulted in suppression of α1,2-fucosylated antigen 
expression on the tumor cells and increased susceptibility to anticancer treatment. 
The mechanisms by which this modification of glycan structures on the cell surface 
influences drug resistance are presently unclear. Fucosylation might modify the glycan chains 
of receptors, which promote or counteract cell death mechanisms. As demonstrated by 
Ichikawa et al. 151, changes in the sugar structures of receptors have the potential to modify 
their function. Alternatively, the sugar can serve as ligand for endogenous lectins eliciting 
signaling pathways with impact for growth control. Indeed, the study of Fischer et al. 129 cited 
above gives an example for distinct glycosylation and growth control via galectins. 
Regulation of immunological functions by cell-type and activation-dependent glycosylation in 
the interplay with selectins or the C-type lectin DC-SIGN provide further important examples 
for a role beyond tumor biology 56. 
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5 Summary 
Galectins are a family of endogenous sugar-epitope-specific receptors (lectins). They 
influence adhesion, growth and invasion in cancer. The clinical relevance of these important 
parameters prompts the question, whether expression profiles of galectins will correlate with 
distinct cell properties. Noteworthy in this respect, homodimeric proto-type galectins regulate 
e.g. neuroblastoma cell growth, and the expression of one of these galectins (galectin-7) is 
enhanced upon p53-induced apoptosis. These facts explain the given focus on the proto-type 
galectins-1, -2 and -7. Their  effects are known to overlap (galectins-1, -2 and -7 in 
neuroblastoma cell growth) or be functionally distinct (induction of apoptosis by galectins-1, 
-2 and -7 in activated T cells). As a key step towards answering the given question, 
establishment of genetically engineered variants of cell lines with ectopic expression of these 
lectins is mandatory. Their availability will then allow evaluating whether and to what extent 
these homologous galectins can contribute to the malignant phenotype in colon cancer. 
Therefore, galectin-specific cDNA was inserted into a vector (pcDNA3.1), which was then 
stably incorporated into the genome of cells of established colon carcinoma cell lines 
(HCT-15, DLD-1). This was verified by PCR analysis on genomic DNA. Subclones with 
different extent of galectin expression were selected to probe for dose dependence of potential 
effects. Systematic measurements of mRNA and protein ascertained gene activity and 
differing levels of galectin synthesis. Their presence was identified on the cell surface as well 
as in cytoplasm and nuclei by fluorescence-activated cell sorting and immunocytochemical 
analysis, respectively. These results provide first evidence for nuclear presence of galectins-2 
and -7 in colon cancer cells. Morphological appearance was not significantly affected. 
Moreover, the doubling time was determined and cell growth was assayed under different 
conditions, i.e. cultivating the cells without/with anchorage, under conditions of reduced 
supply of nutrients, and in the presence of chemotherapeuticals (oxaliplatin, irinotecan, 
SN-38). A marked correlation between galectin expression and proliferation was not 
detectable. No pronounced differences were obtained when comparing data sets of the three 
proto-type galectins. Overall, the successfully generated clones with stable ectopic lectin 
expression are valuable tools for further examining the correlation between galectins and 
tumor biologically relevant parameters. Future analyses will also include histopathologic 
monitoring. 
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